

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 97/15584</b> <b>(43) International Publication Date:</b> 1 May 1997 (01.05.97)
<b>(21) International Application Number:</b> PCT/US96/16482 <b>(22) International Filing Date:</b> 15 October 1996 (15.10.96)  <b>(30) Priority Data:</b> 60/005,146 12 October 1995 (12.10.95) US  <b>(71) Applicant:</b> THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Wolverine Tower, Room 2071, 3003 South State Street, Ann Arbor, MI 48109-1280 (US).  <b>(72) Inventor:</b> PICHESKY, Eran; 325 Burlington Woods Drive, No. 180, Ann Arbor, MI 48104 (US).  <b>(74) Agent:</b> HIGHLANDER, Steven, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> USE OF LINALOOL SYNTHASE IN GENETIC ENGINEERING OF SCENT PRODUCTION  <b>(57) Abstract</b>  A purified S-linalool synthase polypeptide from <i>Clarkia breweri</i> is disclosed as is the recombinant polypeptide and nucleic acid sequences encoding the polypeptide. Also disclosed are antibodies immunoreactive with the purified peptide and with recombinant versions of the polypeptide. Methods of using the nucleic acid sequences, as well as methods of enhancing the smell and the flavor of plants expressing the nucleic acid sequences are also disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

DESCRIPTIONUSE OF LINALOOL SYNTHASE IN  
GENETIC ENGINEERING OF SCENT PRODUCTION

5

BACKGROUND OF THE INVENTION1. Field of the Invention

10       The present invention relates generally to the  
fields of the floral emission of monoterpenes and the  
production of monoterpenes by plants. The present  
invention also relates to the field of the production of  
enhanced scent and taste in plants.

15

2. Description of the Related Art

Flowers of many plants attract pollinators by  
producing and emitting volatile compounds. The scent  
20 emitted by such flowers is often a complex mixture of low  
molecular weight compounds, and the relative abundances  
and interactions of the constituents give the flower its  
particular characteristic fragrance. Floral scents have  
been demonstrated to function as long and short-distance  
25 attractants and nectar guides to a variety of animal  
pollinators (reviewed in Dobson, 1993). Moreover,  
insects are able to distinguish between complex floral  
scent mixtures (Dodson et al., 1969; Pellmyr, 1986).  
Discriminatory visitation based on floral scent has  
30 important implications for population structure and  
reproductive isolation in both temperate (Galen and  
Kevan, 1983; Galen, 1985; Pellmyr, 1986) and tropical  
plant species (Dodson et al., 1969). Thus, floral scent  
is of paramount importance to plant reproduction and  
35 evolution.

- 2 -

Several thousand compounds have been identified from various floral scents, mostly by steam distillation or headspace trapping in combination with gas chromatography-mass spectrometry (GC-MS) (Knudsen et al., 1993). Most of these compounds are either terpenoids, benzenoid compounds, or acyl lipid derivatives (Croteau and Karp, 1991). Although perfumers still survey natural sources for novel fragrance compounds (Joulain, 1987; Kaiser, 1991), this information is most often used in directing organic syntheses to imitate natural fragrances or create new combinations. There is a need, therefore, for purified synthetic enzymes that can be produced in commercial quantities for use in the manufacture of fragrance.

*Clarkia breweri* (Onagraceae), an annual plant native to California, has a strong, sweet fragrance, consisting of some 8-12 different volatiles that fall into two groups: monoterpenoids and benzenoids (Raguso and Pichersky, 1995). A major component of the scent is linalool, an acyclic monoterpene common to the floral scents of numerous other plant species (Kaiser, 1991; Knudsen et al., 1993). Two cyclic isomers of linalool oxide are also produced by *C. breweri* (FIG. 1), almost certainly by further oxidative modification of linalool.

Monoterpenes are a large and diverse group of natural products. Due to their volatility, and thus their ability to be perceived at a distance, they are often involved in plant-insect interactions (Harborne, 1991; Langenheim, 1994). In addition to pollinator attraction (Dobson et al., 1993; Knudsen et al., 1993b), monoterpenes also play an important role in plant defense (Langenheim, 1994; Lewinsohn et al., 1992a) or may act as semio-chemicals (Turlings et al., 1990; Gijzen, 1993). Monoterpenes are also of commercial value as essential oils for perfumery and flavoring use and as industrial

- 3 -

raw materials (Dawson, 1994). Monoterpenes are derived from the ubiquitous isoprenoid intermediate GPP by a class of enzymes called monoterpene synthases (also termed cyclases when they catalyze the formation of cyclic products). Although many monoterpene synthases from plants have been described, only a few of these enzymes have been purified to homogeneity and characterized in detail (Alonso et al., 1992; Lewinsohn et al., 1992b). In addition, few if any of the genes encoding these enzymes have been identified. There is an immediate need, therefore, for the identification and isolation of genes encoding the monoterpene synthases for use in the manufacturing of important chemicals for the fragrance and agronomic industries, and for the engineering of commercially important plants with enhanced characteristics.

#### SUMMARY OF THE INVENTION

The present invention seeks to overcome these and other drawbacks inherent in the prior art by providing a purified linalool synthase polypeptide and by further providing an isolated nucleic acid segment encoding the linalool synthase polypeptide.

As such, an important embodiment of the invention may be described as an isolated nucleic acid segment comprising a nucleic acid sequence encoding a linalool synthase protein or polypeptide. In particular, the nucleic acid sequence may encode an S-linalool synthase polypeptide and may more particularly encode a *Clarkia breweri* S-linalool synthase polypeptide. In even more particular embodiments, the isolated nucleic acid segment of the present invention may encode the amino acid sequence disclosed herein as SEQ ID NO:2.

- 4 -

In certain embodiments, the invention may also be described as a nucleic acid segment comprising a nucleic acid sequence consisting essentially of the nucleic acid sequence of SEQ ID NO:1. It is evident, due to the degeneracy of the genetic code and the functional equivalency of certain amino acids within a polypeptide sequence, that nucleic acid sequences may vary considerably, and still encode essentially the same polypeptide. Therefore, a nucleic acid sequence may be altered for various reasons that include, but are not limited to the use of codons that occur more frequently in the gene sequences of a particular host organism, or to insert or delete a restriction enzyme recognition site for ease in moving the particular sequence into or out of a vector, without altering the function of the polypeptide. So, while it is understood that an embodiment of the present invention is a nucleic acid segment that has the nucleic acid sequence of SEQ ID NO:1, certain variations as described are also encompassed by the present invention.

It will also be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above. This particularly applies to nucleic acid sequences which may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes.

As used herein, the term "nucleic acid segment" is intended to refer to a nucleic acid molecule which has been isolated free of total cellular DNA or RNA, as the case may be, of a particular species. Therefore, a

- 5 -

nucleic acid segment encoding a linalool synthase is intended to refer to a nucleic acid segment which contains such coding sequences yet is isolated away from total RNA or DNA of a *Clarkia breweri* cell. Included within the term "nucleic acid segment", are DNA segments, whether isolated from genomic or cDNA sources or even prepared synthetically, and RNA segments which may be isolated mRNA or RNA obtained by *in vitro* or *in vivo* transcription of a DNA segment, or a chemically synthesized RNA molecule. The term also includes DNA or RNA segments which may be employed in the preparation of vectors, as well as the vectors themselves, including, for example, plasmids, cosmids, phage, viruses, and the like. For example, various types of DNA composition may be used for delivery to recipient cells in accordance with the present invention. For example, DNA segments in the form of vectors and plasmids, or linear DNA fragments, in some instances containing only the DNA element to be expressed in the plant, and the like, may be employed. Vectors, plasmids, cosmids, YACs (yeast artificial chromosomes) and DNA segments for use in transforming such cells will, of course, generally comprise the *Lis* gene. These DNA constructs can further include structures such as promoters, enhancers, polylinkers, or even regulatory genes as desired.

In certain embodiments, the nucleic acid segments of the present invention may be positioned under the control of a promoter, and may even be positioned under the control of a recombinant promoter. For example, the promoter may be in the form of the promoter which is naturally associated with a linalool synthase gene in *Clarkia breweri* cells, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon. In other embodiments, it is contemplated that certain advantages will be gained by positioning the coding nucleic acid segment under the

- 6 -

control of a recombinant, or heterologous, promoter. As used herein, a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a linalool synthase gene in its natural environment. Preferred constructs will generally include a plant promoter such as the CaMV 35S promoter (Odell et al., 1985), or others such as CaMV 19S (Lawton et al., 1987), *nos* (Ebert et al., 1987), *Adh* (Walker et al., 1987), *sucrose synthase* (Yang & Russell, 1990),  $\alpha$ -tubulin, actin (Wang et al., 1992), *cab* (Sullivan et al., 1989), *PEPCase* (Hudspeth & Grula, 1989) or those associated with the R gene complex (Chandler et al., 1989). Other plant promoters are well known in the art as evidenced by the literature (Forde, 1994; Hemleben and Zentgraf, 1994; Wilmink et al., 1995, each incorporated herein by reference) and would function in the practice of the present invention Tissue specific promoters such as root cell promoters (Conkling et al., 1990) and tissue specific enhancers (Fromm et al., 1989) are also contemplated to be particularly useful, as are inducible promoters such as ABA- and turgor-inducible promoters. Naturally, it will be important to employ a promoter that effectively directs the expression of the nucleic acid segment in the cell type chosen for expression. The use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, (for example, see Sambrook et al. (1989); *Methods in Plant Molecular Biology and Biotechnology*, Eds: B.R. Glick, J.E. Thompson. CRC Press, 1993; Gelvin et al., 1990). The promoters employed may be constitutive, or inducible, and can be used under the appropriate conditions to direct high level expression of the introduced nucleic acid segment, such as is advantageous in the large-scale production of recombinant proteins or peptides. Appropriate promoter systems contemplated for use in high-level expression include, but are not limited to, the T7 RNA polymerase promoter



- 7 -

system described by Tabor & Richardson (1985) and the maltose binding protein-fusion protein system (Nagai & Thogersen, 1987).

5           Constructs will also include the *Lis* gene along with  
a 3' end DNA sequence that acts as a signal to terminate  
transcription and allow for the poly-adenylation of the  
resultant mRNA. The most preferred 3' elements are  
10 contemplated to be those from the nopaline synthase gene  
of *Agrobacterium tumefaciens* (Bevan et al., 1983), the  
terminator for the T7 transcript from the octopine  
synthase gene of *Agrobacterium tumefaciens*, and the 3'  
end of the protease inhibitor I or II genes from potato  
or tomato. Regulatory elements such as Adh intron 1  
15 (Callis et al., 1987), sucrose synthase intron (Vasil et  
al., 1989) or TMV omega element (Gallie, et al., 1989),  
may further be included where desired.

          As the DNA sequence between the transcription  
20 initiation site and the start of the coding sequence,  
i.e., the untranslated leader sequence, can influence  
gene expression, one may also wish to employ a particular  
leader sequence. Preferred leader sequences are  
contemplated to include those which include sequences  
25 predicted to direct optimum expression of the attached  
gene, i.e., to include a preferred consensus leader  
sequence which may increase or maintain mRNA stability  
and prevent inappropriate initiation of translation. The  
choice of such sequences will be known to those of skill  
30 in the art in light of the present disclosure. Sequences  
that are derived from genes that are highly expressed in  
plants, and in floral or fruit tissue in particular, will  
be most preferred.

35           It is contemplated that vectors for use in  
accordance with the present invention may be constructed  
to include the ocs enhancer element. This element was

- 8 -

first identified as a 16 bp palindromic enhancer from the octopine synthase (*ocs*) gene of agrobacterium (Ellis et al., 1987), and is present in at least 10 other promoters (Bouchez et al., 1989). It is proposed that the use of  
5 an enhancer element, such as the *ocs* element and particularly multiple copies of the element, will act to increase the level of transcription from adjacent promoters when applied in the context of transformation.

10 Alternatively, one may wish to obtain novel tissue-specific promoter sequences for use in accordance with the present invention. To achieve this, one may first isolate cDNA clones from the tissue concerned and identify those clones which are expressed specifically in  
15 that tissue, for example, using Northern blotting. Ideally, one would like to identify a gene that is not present in a high copy number, but which gene product is relatively abundant in specific tissues. The promoter and control elements of corresponding genomic clones may  
20 then be localized using the techniques of molecular biology known to those of skill in the art.

The production of a transformed cell includes the introduction of an exogenous DNA segment, such as a cDNA  
25 or gene, into a recipient cell to create the transformed cell. The frequency of occurrence of cells receiving DNA is believed to be low. Moreover, it is most likely that not all recipient cells receiving DNA segments will result in a transformed cell wherein the DNA is stably  
30 integrated into the plant genome and/or expressed. Some may show only initial and transient gene expression. However, certain cells from virtually any plant species may be stably transformed, and these cells developed into transgenic plants, through the application of the  
35 techniques known in the art.

- 9 -

There are many methods for introducing transforming DNA segments into cells, but not all are suitable for delivering DNA to plant cells. Suitable methods are believed to include virtually any method by which DNA can be introduced into a plant cell, such as by *Agrobacterium* infection, direct delivery of DNA such as, for example, by PEG-mediated transformation of protoplasts (Omirulleh et al., 1993), by desiccation/inhibition-mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by acceleration of DNA coated particles, etc. In certain embodiments, acceleration methods are preferred and include, for example, microprojectile bombardment and the like.

Where one wishes to introduce DNA by means of electroporation, certain cell wall-degrading enzymes, such as pectin-degrading enzymes, may be employed to render the target recipient cells more susceptible to transformation by electroporation than untreated cells. Alternatively, recipient cells are made more susceptible to transformation, by mechanical wounding.

To effect transformation by electroporation one may employ either friable tissues such as a suspension culture of cells, or embryogenic callus, or alternatively, one may transform immature embryos or other organized tissues directly. One would partially degrade the cell walls of the chosen cells by exposing them to pectin-degrading enzymes (pectolyases) or mechanically wounding the cell in a controlled manner. Such cells would then be recipient to DNA transfer by electroporation, which may be carried out at this stage, and transformed cells then identified by a suitable selection or screening protocol dependent on the nature of the newly incorporated DNA.

- 10 -

A further advantageous method for delivering transforming DNA segments to plant cells is microprojectile bombardment. In this method, particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, gold, platinum, and the like.

An advantage of microprojectile bombardment, in addition to it being an effective means of reproducibly stably transforming plant cells, is that neither the isolation of protoplasts (Cristou et al., 1988) nor the susceptibility to *Agrobacterium* infection is required. An illustrative embodiment of a method for delivering DNA into cells by acceleration is a Biolistics Particle Delivery System, which can be used to propel particles coated with DNA or cells through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with cells cultured in suspension. The screen disperses the particles so that they are not delivered to the recipient cells in large aggregates. It is believed that a screen intervening between the projectile apparatus and the cells to be bombarded reduces the size of projectiles aggregate and may contribute to a higher frequency of transformation by reducing damage inflicted on the recipient cells by projectiles that are too large.

For the bombardment, cells in suspension are preferably concentrated on filters or solid culture medium. Alternatively, immature embryos or other target cells may be arranged on solid culture medium. The cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens are also positioned between the acceleration device and the cells to be bombarded. Through the use of techniques set forth herein one may obtain up to 1000 or more foci of cells transiently expressing a marker gene. The number of cells in a focus

- 11 -

which express the exogenous gene product 48 hours post-bombardment often range from 1 to 10 and average 1 to 3.

5 In bombardment transformation, one may optimize the prebombardment culturing conditions and the bombardment parameters to yield the maximum numbers of stable transformants. Both the physical and biological parameters for bombardment are important in this technology. Physical factors are those that involve  
10 manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells before and immediately after bombardment, the osmotic adjustment of  
15 target cells to help alleviate the trauma associated with bombardment, and also the nature of the transforming DNA, such as linearized DNA or intact supercoiled plasmids. It is believed that pre-bombardment manipulations are especially important for successful transformation of  
20 immature embryos.

Accordingly, it is contemplated that one may wish to adjust various of the bombardment parameters in small scale studies to fully optimize the conditions. One may  
25 particularly wish to adjust physical parameters such as gap distance, flight distance, tissue distance, and helium pressure. One may also minimize the trauma reduction factors (TRFs) by modifying conditions which influence the physiological state of the recipient cells  
30 and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture stage or cell cycle of the recipient cells may be adjusted for optimum transformation.

35

The nucleic acid segments of the present invention may also be defined as recombinant vectors when the

- 12 -

nucleic acid sequences disclosed and described herein are combined with, or joined to nucleic acid sequences that allow the transformation of those sequences into a host cell, and in some cases, replication of those sequences in the host cell. In certain preferred embodiments, the nucleic acid segments may be defined as a recombinant expression vector capable of expressing a linalool synthase protein or polypeptide on introduction into a host cell, or alternatively as a plant transformed with such a recombinant expression vector. In particularly preferred embodiments, the vector comprises a nucleic acid sequence in accordance with SEQ ID NO:1, and the vector may further comprise the pBLUESCRIPT or pBIN19 nucleic acid sequence.

The present invention may, in certain embodiments be defined as a recombinant host cell comprising a nucleic acid segment that encodes a linalool synthase polypeptide. The recombinant host cell may be a prokaryotic cell, such as a bacterial cell, or *E. coli* cell, or the recombinant host cell may be a eukaryotic cell, with a preferred eukaryotic cell being a yeast cell or a plant cell. In addition, the plant cell may be a part of a plant or a substructure of a plant. It is understood that the nucleic acid segment contained in the host cell may be positioned under the control of a promoter and further that the nucleic acid segment may be positioned in a recombinant vector. The recombinant vector may also be a recombinant expression vector wherein the host cell expresses a linalool synthase polypeptide.

In certain embodiments, the invention may be described as a nucleic acid segment hybridizable to a nucleic acid segment comprising the sequence of SEQ ID NO:1 under stringent conditions, or even as consisting essentially of the complement of SEQ ID NO:1. Stringent

- 13 -

conditions are defined as relatively low salt and/or high temperature, such as provided by 0.02M-0.15M NaCl or the equivalent at temperatures of 50°C to 70°C. Such selective conditions tolerate little, if any, mismatch  
5 between the probe and the template or target strand, and would be particularly suitable for isolating linalool synthase genes.

As used herein the term "complement" is used to  
10 define the strand of nucleic acid which will hybridize to the first nucleic acid sequence to form a double stranded molecule under stringent conditions. Stringent conditions are those that allow hybridization between two nucleic acid sequences with a high degree of homology,  
15 but precludes hybridization of random sequences. For example, hybridization at low temperature and/or high ionic strength is termed low stringency and hybridization at high temperature and/or low ionic strength is termed high stringency. The temperature and ionic strength of a  
20 desired stringency are understood to be applicable to particular probe lengths, to the length and base content of the sequences and to the presence of formamide in the hybridization mixture.

25 It is understood in the art that a nucleic acid sequence will hybridize with a complementary nucleic acid sequence under high stringency conditions even though some mismatches may be present. Such closely matched, but not perfectly complementary sequences are also  
30 encompassed by the present invention. For example, differences may occur through genetic code degeneracy, or by naturally occurring or man made mutations and such mismatched sequences would still be encompassed by the present claimed invention.

35

The nucleic acid sequences disclosed her in will also find utility as probes or primers in nucleic acid

- 14 -

hybridization embodiments. As such, it is contemplated that oligonucleotides which comprise a sequence of at least 15, 20, 30, 50, 100, 200, 300, 400, 500, 600, 800, 1000, 1500 or even 2000 contiguous nucleotides which  
5 corresponds to at least a 15, 20, 30, 50, 100, 200, 300, 400, 500, 600, 800, 1000, 1500 or even 2000 nucleotide contiguous sequence of SEQ ID NO:1 or its complement will be useful as probes or primers. In addition, nucleic acid segments comprising a sequence of at least 2,583  
10 contiguous nucleotides which corresponds to a sequence of at least 2,583 contiguous nucleotides of SEQ ID NO:1 or its complement, such as the 2,583 contiguous nucleotides of SEQ ID NO:1 that encode the mature protein, for example will be useful for various embodiments, as will a  
15 segment comprising a sequence of at least 2,610 contiguous nucleotides which corresponds to a sequence of at least 2,610 contiguous nucleotides of SEQ ID NO:1 or its complement, such as the 2,610 nucleotide sequence encoding the entire coding region of SEQ ID NO:1, or even  
20 a nucleic acid segment comprising a sequence of at least 2,681 contiguous nucleotides which corresponds to the 2,681 nucleotide sequence of SEQ ID NO:1 or its complement.

25 It is also understood that the nucleic acid segments may be contained in various vectors and described above, and that as such, a nucleic acid segment of the present invention may be further defined as a nucleic acid fragment derived from SEQ ID NO:1 or its complement  
30 comprising up to 10,000, 5,000, 3,000, 1,000, 500, 100 or even 50 basepairs in length.

In certain embodiments, the invention may also be described as a method of using a nucleic acid segment  
35 encoding a linalool synthase protein or polypeptide, comprising the steps of preparing a recombinant vector in which said nucleic acid segment is positioned under the



- 15 -

control of a promoter; introducing said recombinant  
vector into a host cell; culturing said host cell under  
conditions effective to allow expression of the encoded  
linalool synthase protein or polypeptide; and collecting  
5 said expressed linalool synthase protein or polypeptide.

The invention may also be described in certain  
embodiments as a method of enhancing the scent production  
of a plant, comprising the steps of obtaining a  
10 recombinant vector capable of expressing a nucleic acid  
segment encoding a linalool synthase polypeptide on  
introduction into a plant cell; transforming said plant  
with said vector; and growing said plant under conditions  
appropriate for expression of said nucleic acid segment.  
15 In the practice of this method, the nucleic acid segment  
may be under the control of a tissue specific  
promoter/enhancer, and the tissue specific  
promoter/enhancer may preferably be specific for floral  
tissue. In particularly preferred embodiments, the plant  
20 is a flowering plant, petunia, rose, carnation, etc., for  
example.

The present invention may also be described, in  
certain embodiments as a method of enhancing the flavor  
25 of a plant, comprising the steps of obtaining a  
recombinant vector capable of expressing the nucleic acid  
segment encoding a linalool synthase polypeptide on  
introduction into a plant cell; transforming said plant  
with said vector; and growing said plant under conditions  
30 appropriate for expression of said nucleic acid segment,  
and preferably wherein the nucleic acid segment is under  
the control of a tissue specific promoter/enhancer, and  
more preferably wherein the promoter/enhancer is specific  
for fruit or leaf tissue. Examples of preferred plants  
35 for the practice of this method include, but are not  
limited to tomato, grape and tea plants.

- 16 -

An important embodiment of the present invention is a purified linalool synthase polypeptide having a molecular weight of from about 68 to 79 kDa and a specific activity of at least about 20 pkat/mg or even a  
5 specific activity of at least about 44.1 pkat/mg, or even more preferably a specific activity of at least about 395 pkat/mg. It is understood that a 1 pkat unit is defined as 1 picomole of product formed/second.

10 In certain embodiments, a linalool synthase polypeptide composition of the present invention may be obtained by separating proteins from a flower or a flower part of a *Clarkia breweri* plant. In such a method of obtaining a linalool synthase protein composition, one  
15 would first obtain a protein extract by mechanical or enzymatic cellular disruption and centrifugation. The further purification of such a desired protein is well known in the art and within the skill of the skilled practitioner. For example, if further purification is  
20 desired, one may pass the crude protein extract over a DEAE-cellulose column or an ion-exchange column and collect the fractions with the highest linalool synthase activity. Those fractions may be identified by measuring the absorbance at 280 nm, for example (to determine the  
25 presence of polypeptides), and assaying those fractions containing proteins for linalool synthase activity. Those fractions containing the desired activity may again be further purified if so desired, by pooling those fractions and passing them over a hydroxyapatite column,  
30 for example, and again collecting fractions as before. The collected fractions may be even further purified if desired, by passing those fractions over a Mono-Q column and collecting the fractions with linalool synthase activity to obtain said polypeptide. The polypeptide  
35 obtained by this method may in certain preferred embodiments consist essentially of the amino acid sequence of SEQ ID NO:2.

- 17 -

A certain embodiment of the present invention is also a recombinant polypeptide comprising as a part of its amino acid sequence, a sequence according to the amino acid sequence set forth as SEQ ID NO:2, or even a  
5 recombinant polypeptide that has the amino acid sequence of SEQ ID NO:2.

A certain embodiment of the invention is also an antibody immunoreactive with the polypeptides as defined  
10 immediately above. In addition, the antibody may be a polyclonal antibody, or is more preferably a monoclonal antibody.

Unless defined otherwise, all technical and  
15 scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the  
20 present invention, the preferred methods and materials are now described.

The following abbreviations are used throughout the present disclosure: GPP, Geranyl Pyrophosphate; LIS,  
25 Linalool Synthase; LSC, Liquid Scintillation; DTT, dithiothreitol; GC, Gas chromatography; LPP, Linalyl pyrophosphate; LIS, S-Linalool synthase; Hepes, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; Tris, tris(hydroxymethyl)-aminomethane.

- 18 -

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. The formation of *S*-linalool from GPP by the action of *S*-linalool synthase and subsequent conversion to *S*-linalool oxides. *S*-Linalool synthase and monoterpene cyclases have a similar ionization first step, leading to the intermediate linalyl cation (1). *S*-linalool is formed by water addition in the reaction catalyzed by *S*-linalool synthase, whereas the bound LPP (either *S*- or *R*-LPP, depending on the particular cyclase) is isomerized and cyclized to cyclohexanoid monoterpenes by monoterpene cyclases.

FIG. 2. SDS-PAGE analysis of *S*-linalool synthase throughout purification. M = molecular weight markers (numbers at left indicate kDa). 1. Sample after DEAE-cellulose chromatography (16  $\mu$ g protein); 2. Sample after hydroxyapatite chromatography (8  $\mu$ g protein); 3. After Mono Q anion exchange FPLC (1  $\mu$ g protein); 4. Same as in lane 3 but 2  $\mu$ g protein. The gel was Coomassie-stained as described in Andrews, 1986.

FIG. 3. Gel permeation chromatography of the *C. breweri* *S*-linalool synthase. The Mono Q purified enzyme was separated on a Superdex 75 (Pharmacia FPLC), and gave a molecular mass corresponding to  $73 \pm 5$  kDa by comparison with protein standards: yeast alcohol dehydrogenase ( $M_r$  150,000), bovine serum albumin ( $M_r$  67,000), hen egg white ovalbumin ( $M_r$  45,000), bovine carbonic anhydrase ( $M_r$  29,000) and lysozyme ( $M_r$  14,500).

FIG. 4. Capillary radio-GC analysis of the product of *S*-linalool synthase. The tracing in A is the radioactivity response to the pentane-soluble products generated by incubating *C. breweri* *S*-linalool synthase preparation with [ $^3$ H]-GPP. The tracing in B is the thermal

- 19 -

conductivity detector response to authentic geraniol and linalool standards.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5

Although the importance of scent to the reproductive success of many plants has been well documented, little research in the area of cell and molecular biology has been devoted to it. The inventors' study represents the first example of the isolation and molecular characterization of enzymes and genes involved in scent production. Besides the intrinsic interest in elucidating the mechanisms controlling scent production, such knowledge may accrue practical benefits as well. Some agronomically important plants require pollinators that are attracted by floral scents, and discoveries in this field may eventually lead to improving such crops. For example, some scented tropical trees introduced to the temperate zone are poorly pollinated, with the resulting poor yield, because their scent does not "appeal" to the local insects. Understanding how the production of scent components is regulated may allow us in the future to manipulate such traits and enhance the attractiveness of such flowers to local pollinators.

25

A major component of the scent of *C. breweri* flowers is linalool, an acyclic monoterpene alcohol common to the floral scents of numerous other plant species (Knudsen et al., 1993a; Kaiser, 1991). In addition to linalool, *C. breweri* flowers also synthesize and emit two linalool oxides, for which linalool is the proposed precursor (Winterhalter et al., 1986; Pichersky et al., 1994). The present inventor has previously observed S-linalool synthase (LIS) activity in *Clarkia* flower parts (Pichersky et al., 1994). This enzyme catalyzes the cation-dependent and stereoselective conversion of GPP to S-linalool (FIG. 1). LIS is both developmentally and

35

- 20 -

differentially regulated in the various floral organs (Pichersky et al., 1994). Total LIS activity per flower was highest in petals, from which most of the linalool emission occurs. LIS activity per fresh weight was  
5 highest in stigma and style (i.e., the pistil), but most of the linalool produced by these tissues is converted to linalool oxides by as yet unidentified enzymes. Here the inventors report the purification and characterization of the S-linalool synthase from stigmata of *C. breweri* and  
10 the isolation and characterization of the cDNA gene encoding the S-linalool synthase.

#### GC- MS Characterization of *C. breweri* Volatiles

15 To determine the identity of the volatiles that give *C. breweri* flowers their odor, the technique of headspace scent collection has been used (Dobson, 1993), in which the scent of live flowers is collected and analyzed with a gas chromatograph/mass spectrometer. MS analysis is  
20 done on the peaks as they are eluted, and a computer data base containing several thousand mass spectra is automatically screened for matches. Using this technique, the a total of 12 compounds have been detected from two inbred lines of *C. breweri* plants. The  
25 monoterpene alcohol, linalool, and its trans-pyranoid oxide constituted major fractions of floral volatile output in both lines, as did the aromatic ester, benzyl acetate. The minor aroma constituents included linalool oxide (cis-furanoid), benzyl benzoate, eugenol, methyl  
30 salicylate and vanillin. Four additional compounds, isoeugenol, methyleugenol, methylisoeugenol and veratraldehyde were detected in all flowers from line 2 but were absent in plants from line 1. These 12 compounds fall into two groups, monoterpenes and aromatic  
35 compounds with a benzene skeleton.

- 21 -

In the present studies, abundant headspace compounds were collected from single, living flowers of *C. breweri*. No volatile compounds were detected from similar amounts of floral tissues of the closely related species, *C. concinna*, nor from other *Clarkia* species. When the headspace analyses were repeated with 20-30 living *C. concinna* flowers combined, the compounds linalool, pyranoid linalool oxide and furanoid linalool oxide were detected, but at levels 1000-fold less than in *C. breweri*. No benzenoid compounds were detected in *C. concinna* floral headspace collections.

Developmental and Temporal Variation in Monoterpene Emission by Whole Flowers

To determine the amount of monoterpenes emitted at different stages of floral development, headspace collection was begun with buds on the evening before they opened and ended 6 days later, after flowers had been pollinated and then wilted and abscised. The results indicate that emission of linalool and linalool oxides by *C. breweri* begins as soon as the flowers are open or, in the case of the pyranoid linalool oxide, even slightly before, and reaches a peak on Day 2 (D2). Emission of linalool was the highest, peaking at 49  $\mu\text{g/g}$  fresh weight/12 h. Emission of the pyranoid linalool oxide peaked at 32  $\mu\text{g/g/12 hr}$ . The furanoid linalool oxide was emitted at much lower level, peaking at 2.2  $\mu\text{g/g/12 h}$ . Emission gradually declines after D2 until approximately 24 h after pollination (D3-5), when the flowers drastically decrease their monoterpene output. This cessation coincides with the general senescence of the flower. During the lifespan of the flower, marked variation in monoterpene emission between the day and night periods was not observed. Headspace collections made at 6 h intervals also failed to detect such changes. Diurnal variation has been previously described in some

- 22 -

species (Matile et al., 1988; Overland, 1960) but not in others (Loughrin et al., 1990; Loughrin et al., 1991).

5 Localization and Quantification of Monoterpene Emission  
from the Different Parts of the Flower

To determine the specific parts of the *C. breweri* flowers that emit monoterpenes, living flowers were modified by selectively excising floral parts, so that  
10 only one class of major floral organs (petals, stamens, or style) remained attached to the hypanthium and sepals. Headspace volatiles were then collected from these modified flowers over a 24 h period. The results show that 2/3 of the floral emission of linalool comes from  
15 petals, with the style contributing most of the rest. Emission of linalool per fresh weight is actually higher in the style than in petals, but because the total fresh weight of the style accounts for only 10% of the total mass of the flower while the petals account for 40%, the  
20 petal contribution is predominant. On the other hand, the style is responsible for nearly 100% of emission of the linalool oxides. Sepals, hypanthium and ovaries did not emit monoterpenes. In *C. concinna*, whose flowers emit monoterpenes at a level of 0.1% compared with *C.*  
25 *breweri* (per flower), that emission occurs only from styles. When the emissions of the different floral parts of *C. breweri* were added up, the result closely approximated the complete floral scent both qualitatively and quantitatively, indicating that each part is  
30 autonomous, and therefore synthesis of scent components must occur at the site of emission.

Determination of the level of the monoterpenes found in the flower and bud tissue indicates that there is a  
35 substantial pool of these compounds in the tissue. For example, at the time of peak emission (D2), the amount of linalool in the tissue is approximately equal to 10% of



- 23 -

the total emitted over the corresponding 12 h period. Similar results were found for the linalool oxides. The observations that large pools of these monoterpenes exist within the tissues and that the changes in intracellular  
5 monoterpenes concentration parallel those of monoterpene emission (as does enzyme activity), suggest that these compounds are not sequestered for long as free monoterpenes inside the cell prior to the onset of emission. These observations differ from those made in  
10 *Jasminum* species, in which Watanabe et al. (1993) reported that fragrances were stored as non-volatile glycosides. However, Loughrin et al. (1992) found that the level of glycosidically bound volatiles in *Nicotiana* species was not correlated with the emission levels of  
15 such volatiles but with the age of the flower; older, senescing flowers had higher levels of stored glycosides.

#### Initial Characterization of Linalool Synthase

20 LIS activity was assayed by combining crude extract with  $^3\text{H}$ -GPP (or other substrates) in a buffer containing co-factors. LIS activity was monitored by counting the radioactive linalool extracted from the assay buffer with hexane (GPP is not soluble in hexane) in a scintillation  
25 counter. Radio-GC analyses (Croteau et al., 1990) were also undertaken because GPP could be enzymatically hydrolyzed by non-specific phosphatases to produce geraniol, or the tissue might contain other monoterpene synthases, and geraniol or the other monoterpenes that  
30 may be produced are also soluble in the organic phase. The studies indicated that crude extracts of open *C. breweri* flowers contained substantial amount of soluble LIS activity and no other monoterpene synthases, since the only labelled compound found in the hexane fraction  
35 was linalool. LIS activity was found to require  $\text{Mn}^{2+}$  as a cofactor and GPP as the only substrate. Furthermore,

- 24 -

with a special stereo-GC column it was also shown that the product of the reaction is exclusively S-linalool.

#### Linalool Synthase Activity in Flower Parts

5

To determine the site of, and temporal variation in, linalool synthesis, LIS activity was tested in crude extracts from different parts of flowers and from different stages of development. The results indicate that each flower part that emits linalool also contains significant LIS activity. This observation gives further support to the conclusion that linalool is emitted at or near the site of synthesis. However, there are pronounced differences among floral tissues. The highest and second highest levels of LIS activity per fresh weight were found in the stigma and pistil, respectively, whereas LIS activity in petals was only 20% of LIS activity in stigma at peak time (D1-D2), and activity in stamens was even lower. However, because petals constitute the bulk of the flower, they also possess the highest total amount of LIS activity per flower, which is consistent with the observation that petals emit the highest total amount of linalool per flower.

25 The level of LIS activity is also positively correlated with the rates of linalool emission. Both linalool emission and LIS activity in the petals peak at the D1-D2 period, and as LIS activity decreases afterwards, so does linalool emission. There is some low level of LIS activity in petals of unopened flowers, and some linalool is made in the buds, but apparently not in sufficient amounts to be volatilized. Stigmata and pistils displayed relatively low levels of linalool emission (which is nonetheless also positively correlated with LIS activity) but substantial emission of linalool oxides. Taken together with the observation of high levels of LIS activity in stigmata and pistils, it is

- 25 -

contemplated that most of the linalool produced in these organs is converted into linalool oxides.

Interestingly, a low amount of LIS activity (0.1% compared with *C. breweri* flowers and 3% on a per fresh stigma weight basis) was found in the stigma but not in any other parts of *C. concinna*. Consistent with this observation, emission of linalool and linalool oxides has been found to occur, in trace amounts, only from the stigma of *C. concinna*. The interspecific hybrids, which are somewhat scented, have LIS activity level in the stigma that is 42% that found in *C. breweri* stigma, but their petal LIS activity is only 11% of *C. breweri*. Thus, the *Lis* gene is not unique to *C. breweri*, but is found, and is active, in *C. concinna*. This finding raises the question of the function of the pathway in non-scented plants. In a few cases, linalool production in vegetative tissue in response to insect damage has been observed (Turlings et al., 1992), and it is contemplated that this compound may be used by the plants in such a response. It is contemplated, therefore, that the genes and proteins of the present invention may be useful in the protection of plants from insect damage.

#### 25 Purification and Characterization of LIS

After characterizing the expression of LIS in floral parts throughout the development of the flower, a chromatographical purification protocol was developed that employed anion exchange (DE52) column, HAP column, and another ion-exchange column, FPLC's Mono-Q. As a starting material, a crude extract was prepared from 50 g of stigma tissue (derived from about 20,000 stigmata). The stigmata was used because they have the highest specific activity of LIS (subsequently, LIS was also partially purified from petals, and it appears to be an identical protein). After Mono-Q chromatography, the

- 26 -

fraction containing the peak LIS activity had a single protein, as judged by SDS-PAGE and silver staining. The LIS protein was calculated to have a molecular weight of app. 83 kDa from its migration in the gel. On a  
5 molecular sieving column, LIS activity elutes at about 70 kDa, indicating that LIS is active as a monomer. N-terminal sequencing of LIS eluted from Mono-Q gave a clear sequence (with initial yield >50%) indicating no heterogeneity in the purified enzyme (22 residues were  
10 determined). In addition, the sequences of several internal fragments were determined.

#### Cloning a *Lis* cDNA from *C. breweri*

15 In preparation for cloning the *Lis* gene, mRNA was isolated from petals and stigmata and cDNA expression libraries were prepared in the lambda-ZapII vector (Stratagene, Inc.) Several peptide sequences were used to construct oligonucleotides for PCR (polymerase chain  
20 reaction) using DNA obtained from the cDNA libraries. Fragments in the expected size range were obtained and analyzed.

#### Confirmation of Isolated cDNA Clones of *Lis*

25 The identity of the clones is determined in several ways. First, the oligonucleotide PCR probes are used as sequencing primers to determine the nucleotide sequence of adjacent regions in the clones. Because only parts of  
30 the amino acid sequences which had been obtained are used in the design of the oligonucleotides (7-8 residues out of 20-25 residues per peptide sequence), complete concordance of the predicted amino acid sequence obtained from the nucleotide sequence of the clones with the  
35 peptide sequences is a strong validation of the clones.

- 27 -

Clones that have the correct sequences are further tested by RFLP mapping (McGrath et al., 1993a; McGrath et al., 1993b; Pichersky et al., 1987a; Pichersky et al., 1987b; Pichersky et al., 1988; Pichersky et al., 1989; 5 Pichersky et al., 1991). *F*<sub>1</sub> hybrids between *C. breweri* and *C. concinna* are used to obtain *F*<sub>2</sub>s and *F*<sub>1</sub> X *C. concinna* backcross progeny. These plants are analyzed for emission of linalool and other volatiles. The trait of linalool emission is somewhat quantitative, but two 10 distinct classes of strong emitters and non-emitters are clearly evident. Although the quantitative nature of the trait complicates the genetic analysis, the working hypothesis is that for a progeny to be a strong linalool emitter it has to have inherited the *C. breweri* version 15 of the *Lis* gene, and therefore the putative *Lis* cDNA clones are used as probes to carry out Southern blots of *F*<sub>2</sub> and backcross progeny DNA to look for co-segregation of the *C. breweri Lis* allele with the trait of strong linalool emission. Additional proof of the clone being 20 *Lis* is obtained by expressing the *Lis* cDNA in *E. coli* from the pET T7 promoter and producing antibodies to the protein. The antibodies are then shown to inhibit *Lis* activity from stigma extracts.

25 Final positive proof of the identity of *Lis* clones is obtained by expressing full-length cDNAs in *E. coli* and testing the proteins thus produced for enzyme activity. The preferred expression vector is pET, based on the T7 polymerase and promoter system (Studier et al., 30 1990).

#### Characterization of *Lis* Expression and its Regulation

35 The results indicate that LIS activity in the stigma and petals of *C. breweri* is substantial, whereas LIS activity in the stigma of *C. concinna* is 3% that of the corresponding *C. breweri* tissue (per fresh weight) and

- 28 -

non-detectable in petals. Thus, linalool emission by *C. breweri* flowers is correlated with greater than a 30-fold or more increase of LIS activity in *C. breweri* flowers. Because the partially purified *C. breweri* petal LIS is  
5 essentially identical in its molecular and enzymatic properties to the stigma protein, and so is the *C. concinna* stigma LIS enzyme, the differences in the levels of LIS activity among *C. breweri* stigma, petals, and *C. concinna* stigma are not believed to be due to  
10 changes in turn-over number or other kinetic parameters of the enzyme. On the other hand, these differences are strongly correlated with the differences in the amount of protein. Thus, it appears that *C. breweri* has evolved the ability to make (and emit) greater amounts of  
15 monoterpenes by increasing the level of *Lis* gene transcription and/or increasing translational efficiency.

Expression levels of the *Lis* gene in stigma and petals in the two species may be determined by first  
20 determining the steady-state level of the mRNA with the Northern blotting technique, using the *Lis* cDNA clone as a probe, and also by primer extension, a technique that also allows the determination of the start of transcription (Kellman et al., 1990; Kellman et al.,  
25 1993; Piechulla et al., 1991). Run-on transcription assays may also be used to measure rates of transcription (Giuliana et al., 1988b). A correlation is then sought between transcription rates and steady-state mRNA levels, and between steady-state mRNA and LIS  
30 activity levels. Higher or lower levels than expected of mRNA compared with transcription rate suggests post-transcriptional control, and a discrepancy between steady-state mRNA level and LIS activity suggests translational or post-translation regulation as well,  
35 such as protein stability differences.

- 29 -

The nucleic acid segments of the present invention may also be used to isolate and characterize the *Lis* genes from various tissues in both species by screening genomic libraries constructed in the lambda vector EMBL3.

5 In light of the present discovery, the promoter region of the *C. breweri Lis* gene may now be characterized by *in vivo* methods, such as reporter gene constructs, for example, and used for tissue specific expression of foreign genes. This may be done by the use of a

10 promoterless reporter gene, GUS (Jefferson, 1987), to which the *Lis* promoter, intact or truncated, may be fused. Several constructs may be made, each missing a certain part of the *Lis* promoter. These constructs would preferably be used to transform *Nicotiana tabacum* SR1

15 plants, using the binary vector system of the Ti plasmid of *Agrobacterium tumefaciens* (An et al., 1986). Plants are regenerated, and optimal sequences for various promoter functions may thus be identified by the effect that their removal has on GUS activity (visualized by the

20 addition of the GUS substrate to detached whole or sectioned organs).

#### Cellular and Subcellular Localization of LIS

25 The cellular and intracellular location of monoterpene synthesis is of considerable interest. In some plants that produce monoterpenes as defense compounds, special structures, such as leaf trichomes or resin glands (in stem tissue) have evolved where

30 monoterpene synthesis takes place (Gershenzon et al., 1993; Lewinsohn et al., 1991). Neither light microscopy nor electron scanning microscopy has detected any specialized floral structures such as papillate cells or granular trichomes (see Stern et al., 1987) that could be

35 responsible for volatile production or emission.

- 30 -

To determine which types of cells within a tissue such as the stigma contain *Lis* mRNA, the *in situ* hybridization technique may be used (Cox et al., 1988). The use of this technique is necessary because in plants, different types of cells may exist in a one-layer region and they cannot easily be separated in amounts large enough to extract mRNA. The present invention allows one to perform immunofluorescence assays (Baskin et al., 1992) using anti-LIS antibodies disclosed herein.

### Antibodies

In another aspect, the present invention comprises an antibody that is immunoreactive with a linalool synthase polypeptide. An antibody can be a polyclonal or a monoclonal antibody and is preferably a monoclonal antibody. Means for preparing and characterizing antibodies are well known in the art (See, e.g., Antibodies "A Laboratory Manual, E. Howell and D. Lane, Cold Spring Harbor Laboratory, 1988).

Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogen comprising a polypeptide of the present invention and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of antisera. Typically an animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster or a guinea pig. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

To obtain monoclonal antibodies, one would also initially immunize an experimental animal, often preferably a mouse, with an LIS composition. One would then, after a period of time sufficient to allow antibody generation, obtain a population of spleen or lymph cells



- 31 -

from the animal. The spleen or lymph cells can then be fused with cell lines, such as human or mouse myeloma strains, to produce antibody-secreting hybridomas. These hybridomas may be isolated to obtain individual clones which can then be screened for production of antibody to the LIS polypeptide.

Following immunization, spleen cells are removed and fused, using a standard fusion protocol (see, e.g., The Cold Spring Harbor Manual for Hybridoma Development, incorporated herein by reference) with plasmacytoma cells to produce hybridomas secreting monoclonal antibodies against LIS. Hybridomas which produce monoclonal antibodies to the selected antigens are identified using standard techniques, such as ELISA and Western blot methods.

It is proposed that monoclonal antibodies specific to the particular LIS enzyme may be utilized in immunoabsorbent protocols to purify native or recombinant LIS enzyme species or variants thereof.

In general, both poly- and monoclonal antibodies against LIS may be used in a variety of embodiments. For example, they may be employed in antibody cloning protocols to obtain cDNAs or genes encoding LIS or related proteins. They may also be used in inhibition studies to analyze the effects of LIS in particular cells or tissue types. A particularly useful application of such antibodies is in purifying native or recombinant LIS, for example, using an antibody affinity column, or screening for *Lis* expressing cells. The operation of all such immunological techniques will be known to those of skill in the art in light of the present disclosure.

- 32 -

Biological Functional Equivalents

Modification and changes may be made in the structure of the encoded polypeptides used in the vectors and nucleic acid segments of the present invention and still obtain a functional molecule that encodes a protein or peptide with desirable characteristics. The following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. The amino acid changes may be achieved by changing the codons of the DNA sequence, according to the following codon table:

Table 1

15	Amino Acids		Codons					
	Alanine	Ala	A	GCA	GCC	GCG	GCU	
	Cysteine	Cys	C	UGC	UGU			
	Aspartic acid	Asp	D	GAC	GAU			
	Glutamic acid	Glu	E	GAA	GAG			
20	Phenylalanine	Phe	F	UUC	UUU			
	Glycine	Gly	G	GGA	GGC	GGG	GGU	
	Histidine	His	H	CAC	CAU			
	Isoleucine	Ile	I	AUA	AUC	AUU		
	Lysine	Lys	K	AAA	AAG			
25	Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG
	Methionine	Met	M	AUG				
	Asparagine	Asn	N	AAC	AAU			
	Proline	Pro	P	CCA	CCC	CCG	CCU	
	Glutamine	Gln	Q	CAA	CAG			
30	Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG
	Serine	Ser	S	AGC	AGU	UCA	UCC	UCG
	Threonine	Thr	T	ACA	ACC	ACG	ACU	

- 33 -

Table 1 (continued)

Amino Acids		Codons				
Valine	Val	V	GUA	GUC	GUG	GUU
Tryptophan	Trp	W	UGG			
Tyrosine	Tyr	Y	UAC	UAU		

5           For example, certain amino acids may be substituted  
for other amino acids in a protein structure without  
appreciable loss of interactive binding capacity with  
structures such as, for example, binding sites on  
substrate molecules. Since it is the interactive  
10       capacity and nature of a protein that defines that  
protein's biological functional activity, certain amino  
acid sequence substitutions can be made in a protein  
sequence, and, of course, its underlying DNA coding  
sequence, and nevertheless obtain a protein with like  
15       properties. It is thus contemplated by the inventors  
that various changes may be made in the peptide sequences  
of the linalool synthase proteins, or corresponding DNA  
sequences which encode said proteins without appreciable  
loss of their biological utility or activity.

20           In making such changes, the hydropathic index of  
amino acids may be considered. The importance of the  
hydropathic amino acid index in conferring interactive  
biologic function on a protein is generally understood in  
25       the art (Kyte and Doolittle, 1982, incorporate herein by  
reference). It is accepted that the relative hydropathic  
character of the amino acid contributes to the secondary  
structure of the resultant protein, which in turn defines  
the interaction of the protein with other molecules, for  
30       example, enzymes, substrates, receptors, DNA, antibodies,  
antigens, and the like.

Each amino acid has been assigned a hydropathic  
index on the basis of their hydrophobicity and charge

- 34 -

characteristics (Kyte and Doolittle, 1982), these are:  
isoleucine (+4.5); valine (+4.2); leucine (+3.8);  
phenylalanine (+2.8); cysteine/cystine (+2.5); methionine  
(+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7);  
5 serine (-0.8); tryptophan (-0.9); tyrosine (-1.3);  
proline (-1.6); histidine (-3.2); glutamate (-3.5);  
glutamine (-3.5); aspartate (-3.5); asparagine (-3.5);  
lysine (-3.9); and arginine (-4.5).

10 It is known in the art that certain amino acids may  
be substituted by other amino acids having a similar  
hydropathic index or score and still result in a protein  
with similar biological activity, i.e., still obtain a  
biological functionally equivalent protein. In making  
15 such changes, the substitution of amino acids whose  
hydropathic indices are within  $\pm 2$  is preferred, those  
which are within  $\pm 1$  are particularly preferred, and those  
within  $\pm 0.5$  are even more particularly preferred.

20 It is also understood in the art that the  
substitution of like amino acids can be made effectively  
on the basis of hydrophilicity. U.S. Patent 4,554,101,  
incorporated herein by reference, states that the  
greatest local average hydrophilicity of a protein, as  
25 governed by the hydrophilicity of its adjacent amino  
acids, correlates with a biological property of the  
protein.

As detailed in U.S. Patent 4,554,101, the following  
30 hydrophilicity values have been assigned to amino acid  
residues: arginine (+3.0); lysine (+3.0); aspartate  
(+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3);  
asparagine (+0.2); glutamine (+0.2); glycine (0);  
threonine (-0.4); proline (-0.5  $\pm$  1); alanine (-0.5);  
35 histidine (-0.5); cysteine (-1.0); methionine (-1.3);  
valine (-1.5); leucine (-1.8); isoleucine (-1.8);  
tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

- 35 -

It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

20

#### Site-Specific Mutagenesis

Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer

- 36 -

of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

5           In general, the technique of site-specific mutagenesis is well known in the art, as exemplified by various publications. As will be appreciated, the technique may employ a phage vector which exists in both a single stranded and double stranded form. Typical  
10   vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially available and their use is generally well known to those skilled in the art. Double stranded  
15   plasmids are also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage.

          In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-  
20   stranded vector or melting apart of two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes the desired peptide. An oligonucleotide primer bearing the desired mutated  
25   sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the  
30   synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then  
35   used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

          The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed

- 37 -

mutagenesis is provided as a means of producing potentially useful species and is not meant to be limiting, as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

#### EXAMPLE 1

##### Localization of Monoterpene Emission and LIS Activity

##### Plant Material, Growth Conditions, Headspace Collection, GC-MS Analysis

Details of *C. breweri* and *C. concinna* stocks and growing conditions, dynamic headspace collection on Tenax and activated charcoal sorbents, and chemical analyses via GC-MS are as described in Raguso and Pichersky (1995). All headspace collections were performed in a Convirion growth chamber under a 12 h light/ 12 h dark photoperiod. Temperature was set to 25°C during the light period and 18°C during the dark period. In all

- 38 -

experiments, headspace collections from ambient air and from vegetative tissues were used as controls.

#### Time Course of Scent Production

5

Volatile monoterpenoid production in individual flowers of four separate plants was monitored over a 7 d period beginning on the day before anthesis and continuing until floral abscission. Headspace volatiles were collected as described in Raguso and Pichersky (1995). The collections were made at 12 h intervals, corresponding to the dark and light periods in the growth chamber. All flowers were hand-pollinated with a cotton swab on the evening of day 3 after anthesis in order to simulate the typical life cycle of a *C. breweri* flower.

#### Localization and Quantification of Monoterpene Synthesis in Floral Parts

20

The specific floral parts responsible for scent emission were determined and the emission levels were quantified by collection of headspace volatiles from attached, second day (hermaphroditic) intact flowers and from same-stage flowers in which floral organs had been systematically removed, to leave only petals, only anthers or only the style. In order to detect all volatiles emitted by a given flower part, which could possibly emit different compounds at different times, a 24 h collection period was used. To determine diurnal variation in the emission of a given compound, headspace collections were taken over 6 and 12 hr intervals.

30

#### Monoterpene Extraction

35

Whole flowers representing the phenological spectrum from anthesis to abscission were excised at the base of the hypanthium, weighed and macerated with a glass rod in



- 39 -

1 mL of HPLC-grade hexane at ambient temperature, then stored in the dark at -20°C. Samples were concentrated to a volume of 75  $\mu$ L under a flow of gaseous N<sub>2</sub> and 15  $\mu$ L of a 0.3% (v/v) solution of geraniol in hexane were added as an internal standard. Four  $\mu$ L of each sample were then used for GC-MS analysis.

### Linalool Synthase Enzyme Extraction and Assay

#### 10            *Enzyme extraction*

A crude protein extract was prepared by macerating flower parts in a microcentrifuge tube in the presence of ice-cold buffer (10 volumes:fresh weight) containing 50 mM BisTris-HCl pH 6.9, 10 mM DTT, 5 mM Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub>, 1% (w/v) PVP-40 and 10% (v/v) glycerol. The slurry was centrifuged for 10 min and the supernatant transferred to a new tube. For each time point, extracts of 3 to 5 flowers from 3 different plants were combined.

20

#### *Enzyme Assay and Product Analysis*

Linalool synthase activity was assayed by diluting 10  $\mu$ L of crude extract (1.5-3  $\mu$ g protein) into 80  $\mu$ L of assay buffer (50 mM potassium HEPES pH 7.8, 5 mM DTT, 5 mM sodium metabisulfite, 10% (v/v) glycerol, 20 mM MgCl<sub>2</sub> and 5 mM MnCl<sub>2</sub> [Lewinsohn et al., 1991]), adding 10  $\mu$ L of [1-<sup>3</sup>H]-GPP to final concentration 16  $\mu$ M, at 150 mCi/mol [substrate synthesized according to Croteau and Cane (1985)], and overlaying the mixture with either pentane or hexane to trap volatile metabolites. The tube was then vortexed briefly and incubated at 20°C for 1 h. Appropriate controls included the omission of crude extract, the use of boiled crude extracts, the omission of substrate and/or cations, and the substitution of other potential substrates such as (3R)- and (3S)-[1-<sup>3</sup>H]-linalyl pyrophosphate.

- 40 -

After 1 h, the tube was vortexed again and the amount of the radioactive linalool product, which partitioned into the organic phase, was determined by an LSC of an aliquot. Radio-GC analysis (Croteau and Satterwhite, 1990) of labelled products in the organic phase was also undertaken to examine the formation of geraniol (liberated from the substrate by phosphatases) and to determine whether other monoterpene synthases were present in the extracts. These radio-GC analyses showed that no floral tissue contained detectable monoterpene synthase activity other than LIS (linalool > 95% of product by coincidence of radioactivity with authentic standard), and that only crude extracts from mature pollen grains contained appreciable phosphatase activity. Because of the presence of phosphatases in the pollen grains, anther tapeta were routinely excluded in the preparation of subsequent cell-free extracts.

#### Temporal Variation in Scent Emission by Intact Flowers

Under the present growing conditions, the first buds become visible on the *C. breweri* plant 4-6 weeks after germination. The closed buds develop for approximately 12-18 d before the fused sepals split and reflex, allowing the petals to open (anthesis). Anthesis in *C. breweri* typically occurs in the morning. Flowers that have been pollinated at any time after Day 2 past anthesis, when stigma lobes recurve and become receptive, will begin to wilt within 24 h of pollen deposition. After 6-7 d, unpollinated flowers also begin to senesce and wilt. The present inventor has previously shown (Raguso and Pichersky, 1995) that three monoterpenes - linalool, furanoid linalool oxide and pyranoid linalool oxide - are constituents of the scent of *C. breweri* flowers. In order to determine the amount of monoterpenes emitted at different stages of floral development, time-course headspace collections were

- 41 -

performed at 12 h intervals, followed by GC-MS analysis. Headspace collection was performed with buds on the evening before they opened and ended 6 d later, after flowers had been pollinated and then wilted and abscised.

5

Unopened flowers (buds) emitted no linalool or furanoid linalool oxide, but they did emit small amounts of pyranoid linalool oxide. Significant emission of all three monoterpenes began at anthesis and peaked during Day 2, and afterwards began a gradual decline. Monoterpene emission was still high on the evening of Day 4, 24 h after hand pollination, and then rapidly declined. Overall, the emission of linalool by the intact flowers was higher than the corresponding oxides, peaking at 8.5  $\mu\text{g}/\text{flower}/12\text{ h}$ . Emission of the pyranoid linalool oxide peaked at 5.9  $\mu\text{g}/\text{flower}/12\text{ h}$ . The furanoid linalool oxide was emitted at much lower level, peaking at 0.4  $\mu\text{g}/\text{flower}/12\text{ h}$ . Senescence (wilting) of all flowers was observed by the morning of Day 5, yet low levels of linalool and linalool oxides were emitted until abscission on the evening of Day 6.

#### Quantitation of Monoterpenes in Flower Tissue

The amounts of monoterpenes in intact flowers at different developmental stages were determined by hexane extraction and GC-MS analysis. The three monoterpenes were detectable in mature buds 2-3 d from anthesis. Tissue levels of linalool peaked on the evening of Day 2 and then declined, paralleling the pattern found for linalool emission. The maximal level of linalool found in the flower tissue was approximately 10% of the amount of linalool emitted by the flower over a 12 h period. Tissue levels of linalool oxides peaked at Day 3, while the emission of linalool oxides was highest at Day 2. On Day 2, levels of linalool oxides in the tissue constituted approximately 10% of the emission levels of

- 42 -

these compounds over a 12 h period, but on Day 3 this ratio increased to 20% to 60%.

5     Localization and Quantification of Monoterpene Emission  
      from the Different Parts of the Flower

*C. breweri* flowers

10       To determine the specific parts of the *C. breweri*  
      flowers that emit monoterpenes, studies were performed in  
      which living flowers were modified by selectively  
      excising floral parts, so that only one class of major  
      floral organ (petals, stamens, pistil) remained attached  
      to the hypanthium and sepals. Headspace volatiles were  
15       then collected from these modified flowers over a 24 h  
      period. The data obtained were used to calculate the  
      contribution of each part to the total emission of the  
      flower (Table 2), and also the emission of each part  
      relative to its weight (Table 3). These data revealed  
20       that the majority of the linalool emission came from the  
      petals, although substantial emission was also detected  
      from the pistil (1/3 of the amount emitted by the petals)  
      and some linalool was emitted by the stamens (1/10 of the  
      petal emission). On the other hand, pyranoid linalool  
25       oxide and furanoid linalool oxide were emitted almost  
      exclusively by the pistil.

*C. concinna* flowers

30       *C. concinna*, a close relative of *C. breweri*, has  
      flowers which are smaller and which do not emit a  
      detectable scent. A previous investigation revealed that  
      *C. concinna* flowers do emit low levels of linalool and  
      linalool oxides (0.1% of emission compared with *C.*  
35       *breweri*) (Raguso and Pichersky, 1995). The levels of  
      emission of these monoterpenes in floral organs of *C.*

- 43 -

concinna (Tables I,II) were then examined. The results indicate that volatile emission occurs only in pistils.

#### Linalool Synthase Activity in Flower Parts

5

##### *Linalool synthase activity in flowers*

To determine the site of synthesis of linalool and the temporal variation in its synthesis, crude extracts  
10 were prepared from different parts of the flowers that had been open for 1 to 6 days and these extracts were assayed for activity of linalool synthase, the enzyme that catalyzes the conversion of GPP to linalool. In these studies, the flower was dissected into smaller  
15 parts than was possible in the headspace collection of modified live flowers detailed above. For example, in the headspace collection it was not logistically possible to measure the contribution of the stigma separately from that of the rest of the pistil. However, in preparing  
20 crude extracts from different parts of the flower this limitation was overcome.

LIS activity was found in several parts of the flowers. At the peak of LIS activity, at Days 1-2, total  
25 LIS activity was similar in petals and pistil (stigma + style). However, stigmata possessed the highest level of LIS activity per fresh weight, followed by style tissue (with 25-35% of the specific activity found in stigma), petals (20% of stigma LIS specific activity at peak time)  
30 and stamens. None of the remaining floral parts - sepals, hypanthium and ovaries - were found to contain any LIS activity. The vegetative parts of the plant were also devoid of LIS activity.

35 Levels of LIS activity varied during the lifespan of the flower in concert with the levels of linalool emission and its concentration in floral tissue. Maximal

- 44 -

LIS activity was observed during Days 1-2. When flowers were pollinated on Day 3, LIS activity decreased by 90% in the stigma and 50% in the petals within 48 h, similar to the reduction in monoterpene emission following  
5 pollination. However, when pollination did not occur, LIS activity in the different floral organs declined only slowly from the peak levels over the next few days.

*Linalool synthase activity in buds*

10

Since freshly opened flowers already contain substantial enzyme activity, the level of LIS activity was investigated in buds. In order to carry out these studies, it was necessary to devise a method to classify  
15 stages in bud development. Due to variation in bud size and maturation time within and among plants, it was difficult to predict the exact number of days remaining before anthesis by bud size alone. However, in contrast to bud size, color changes during the development of the  
20 petals and stigma were found- a progression from white to dark purple - to be reliable markers for the developmental stage of the bud. These indicators were used to denote five stages in bud development. Each stage lasts approximately 2-3 days, for a total of 12-18  
25 days preceding anthesis. In addition, because the small size of some floral organs within buds precluded obtaining enough material for enzyme assays, only petals and pistils were examined for LIS activity. Whereas the youngest buds (stages 1 and 2) had no detectable LIS  
30 activity, pistils (but not petals) of third stage buds already possessed appreciable LIS activity (approximately 30% of peak level). By stage 5, levels of LIS activity in the petals were close to or at the peak levels found in petals of open flowers.

- 45 -

*Linalool synthase activity in flowers of C. concinna*

The LIS activity in extracts of *C. concinna* flower parts of Day 2 flowers was examined. Consistent with the  
5 emission data (Tables I,II), LIS activity was detected only in the stigma, which had a level of activity of 2.8 fkat/stigma (and per flower) and 4.6 fkat/g fresh weight. These levels are respectively 0.3% of the LIS activity per stigma (0.01% per flower) and 3% per fresh weight of  
10 activity in *C. breweri* stigmata of the equivalent stage.

Temporal Variation in Scent Production by Whole Flowers and Buds

15 The strong, sweet floral scent of *C. breweri* is unique in its genus, and is correlated with pollination by moths, a mode of reproduction that is novel among *Clarkia* species (MacSwain et al., 1973). Emission of the monoterpene components of the scent begins as soon as  
20 the flowers are open and reaches a peak on Day 2. During the lifespan of the flower, marked variation in monoterpene emission between the day and night periods was not observed. It is possible that temporary, but substantial, increases or decreases in emission were  
25 missed because of their short duration, but headspace collections made at 6 h intervals also failed to detect such changes, and samples did not vary by more than a factor of 1.5. Daily cycling in emission of linalool and other floral scent components, with a nocturnal peak in  
30 intensity coinciding with periods of moth activity, is a feature of many moth-pollinated flowers, such as *Cestrum nocturnum* (Solanaceae) (Overland, 1960; Matille and Altenberger, 1988). However, in other moth-pollinated flowers, such as *Nicotiana glauca* (Solanaceae), rates  
35 of linalool emission do not differ appreciably between night and day (Loughrin et al., 1990, 1991).

- 46 -

Localization and Quantification of Monoterpene Emission  
from the Different Parts of the Flower

The data (Table 2) show that 2/3 of the floral  
5 emission of linalool comes from petals, with the style  
contributing most of the rest. Emission of linalool per  
fresh weight is actually higher in the pistil than in  
petals (Table 3), but because the total fresh weight of  
10 the pistil accounts for only 10% of the total mass of the  
flower while the petals account for 40% (Table 4), the  
petal contribution is predominant. On the other hand,  
the pistil is responsible for nearly 100% of floral  
emission of the linalool oxides. When the emissions of  
15 the different floral parts are added up, the results  
closely approximate the complete floral scent both  
qualitatively and quantitatively, indicating that each  
part is autonomous and thus syntheses of scent components  
occur at the sites of emission. Previous studies (Dobson  
20 et al., 1990; Knudsen and Tollsten, 1991) also found that  
different parts of flowers emit different relative  
amounts of scent components, although absolute quantities  
were not reported.

The observations that relatively small pools of free  
25 monoterpenes exist within the tissues, and that the  
changes in tissue monoterpene concentrations parallel  
those of monoterpene emission suggest that these  
compounds are not appreciably sequestered as free  
monoterpenes inside the cell prior to the onset of  
30 emission but are emitted as soon as they are made. The  
absence of both appreciable pools of scent volatiles and  
the biosynthetic enzymes of such compounds in mature  
floral tissue of *Jasminum* species prompted Watanabe et  
al. (1993) to discover that fragrance components were  
35 stored as non-volatile glycosides. However, Loughrin et  
al. (1992) found that the level of glycosidically bound  
volatiles in *Nicotiana* species was not correlated with



- 47 -

the emission levels of such volatiles but with the age of the flower; older, senescing flowers had higher levels of stored glycosides. The presence of glycosidically bound monoterpenes in *Clarkia* flowers has not yet been examined. However, the presence in mature *C. breweri* flowers of LIS and, likely, the other enzymes in the pathway suggests that if such stored, modified monoterpenes are present, they might not contribute to scent emission, or their contribution might not be essential.

#### Linalool Synthase Activity in Flower Parts

The highest and second highest levels of LIS activity per fresh weight were found in the stigma and style, respectively. The pistil is the only part of the flower (excluding the ovaries) that continues to increase in size and weight after the flower opens, but its specific LIS activity does not decrease, indicating that additional LIS activity accrues there, at least during the first few days after anthesis. However, the petals constitute the bulk of the LIS-containing floral tissue (Table III), and they possess a similar or even higher total amount of LIS activity compared with the pistil. Each flower part that emits linalool or linalool oxides - petals, pistils and stamens - also contains significant LIS activity, whereas flower parts that do not contain LIS activity do not contain or emit these monoterpenes. These observations lend further support to the conclusion based on the determination of emission from flowers in which a single part was left that linalool and its oxides are emitted at or near the site of synthesis and that translocation is probably not of significance.

The levels of LIS activity in the different parts of the flower throughout the lifespan of the flower are also positively correlated with the rates of emission of

- 48 -

linalool and the two linalool oxides. Both monoterpene emission and LIS activity in the petals, pistil and stamens peak during the first two days after anthesis, and as LIS activity decreases afterwards (especially after the flower has been pollinated), so do linalool and linalool oxides emissions. However, buds of later stages contain appreciable amounts of LIS activity but they do not accumulate or emit these monoterpenes. It is likely that earlier steps in the pathway are not yet operating in the buds, either for lack of other enzymes or because of sequestration of enzymes and/or substrates in different subcellular compartments. Alternatively, monoterpenes may be synthesized in buds of later stages but may be rapidly converted to other compounds or derivatives.

The pistil displayed relatively low levels of linalool emission but substantial emission of linalool oxides (Table 2). Taken together with the observation of high levels of LIS activity in stigma and style, the conclusion is inescapable that most of the linalool produced in these organs is converted into linalool oxides. Winterhalter et al. (1986) presented evidence that, in papaya tissues, the linalool oxides are synthesized from linalool via 6,7-epoxylinalool as an intermediate (FIG. 1). They further showed that the conversion of linalool to 6,7-epoxylinalool was enzymatically catalyzed, although a specific enzyme was not identified. The enzyme(s) responsible for the formation of the linalool oxides from 6,7-epoxylinalool, if such exist, have also not yet been identified.

Interestingly, a low amount of LIS activity (0.1% compared with *C. breweri* flowers and 3% on a per fresh stigma weight basis) is found in the stigma but not in any other parts of the flowers of *C. concinna*, a species that has no discernable floral scent (Raguso and

- 49 -

Pichersky, 1995) and is not pollinated by moths (MacSwain et al., 1973). However, linalool and both linalool oxides have been detected, albeit in trace amounts, in the headspace of flowers of *C. concinna* (0.1% of that of *C. breweri*) (Table I and Raguso and Pichersky, 1995), and this emission has now been traced to the pistil (Tables 2, 3). The observation that LIS activity and monoterpene synthesis occur in the pistil of an essentially non-scented flower raises the possibility that linalool and/or the linalool oxides may have some physiological function in this organ which is unrelated to attracting pollinators.

TABLE 2  
Emission of Monoterpenes from Flower Parts  
of *C. breweri* and *C. concinna*,  
24 h Collection Beginning on d 2

Species	Linalool		Pyranoid Linalool Oxide		Furanoid Linalool Oxide	
	$\mu\text{g}$	% total	$\mu\text{g}$	% total	$\mu\text{g}$	% total
<i>C. breweri</i>						
Stamens (n=5)	1.31 $\pm$ 0.59	5.60	0.01 $\pm$ 0.01	0.02	0.00 $\pm$ 0.01	0.42
Pistil (n=8)	4.78 $\pm$ 2.84	20.30	28.44 $\pm$ 5.35	129.00	0.62 $\pm$ 0.12	52.00
Petals (n=7)	14.08 $\pm$ 4.01	60.25	0.09 $\pm$ 0.05	0.40	ND <sup>a</sup>	ND
Whole flowers (n=23)	23.37 $\pm$ 1.72	100.00	22.74 $\pm$ 1.61	100.00	1.19 $\pm$ 0.13	100.00
<i>C. concinna</i>						
Stamens (n=3)	ND	ND	ND	ND	ND	ND
Pistil (n=3)	0.024 $\pm$ 0.002	100.00	0.028 $\pm$ 0.001	100.00	0.001 $\pm$ 0.001	100.00
Petals (n=3)	ND	ND	ND	ND	ND	ND
Whole flowers (n=3)	0.024 $\pm$ 0.002	100.00	0.03 $\pm$ 0.001	100.00	0.001 $\pm$ 0.001	100.00
<sup>a</sup> ND, Not detected.						

5

10

15

-51-

TABLE 3  
Emission of Monoterpenes from Flower Parts  
of *C. breweri* and *C. concinna*;  
24 h Collection Beginning on d 2

Species	Linalool	Pyranoid		Furanoid	
		Linalool	Oxide	Linalool	Oxide
<i>C. breweri</i>					
Stamens (n=5)	54.5±24.4	0.2±0.2	0.2±0.2		
Pistil (n=8)	296.0±177.6	1840.0±334.5	39.0±7.7		
Petals (n=7)	220.0±62.7	1.4±0.8	ND <sup>a</sup>		
<i>C. concinna</i>					
Stamens (n=3)	ND	ND	ND		
Pistil (n=3)	8.1±0.8	9.4±0.4	0.3±0.2		
Petals (n=3)	ND	ND	ND		
<sup>a</sup> ND, Not detected.					

5

10

15

- 52 -

TABLE 4

Weight Distribution in Different Parts  
of the *C. breweri* Flower

	Flower Part	Total Wt	Percent of Total
5		mg	
	Stamens	24.0 $\pm$ 2.0	15.1
	Pistil	16.0 $\pm$ 3.0	10.1
	Stigma	6.0 $\pm$ 0.5	3.8
	Style	10.0 $\pm$ 0.7	6.3
10	Petals	64.0 $\pm$ 1.0	40.2
	Hypanthium and sepals	55.0 $\pm$ 7.0	34.6
	Whole flower (without ovaries)	159.0 $\pm$ 8.0	100.0

15

**EXAMPLE 2****Purification and Characterization of S-Linalool Synthase**Plant Materials, Substrates and Reagents

20

Details of *C. breweri* stocks and growing conditions are described in Raguso and Pichersky (1995). Stigmata from freshly opened flowers (not more than 2 days after anthesis) were used for enzyme isolation, as this tissue has been shown to contain very high levels of LIS per

25

gram of tissue (Pichersky et al., 1994). S-linalool was purified from coriander oil, and R-linalool was from Ho wood (both from Berje Chemical Products, Long Island City, NY). [1-<sup>3</sup>H]-GPP, and 3R- and 3S-[1-<sup>3</sup>H]-LPP were synthesized as previously described (Croteau et al.,

30

1994).

- 53 -

Enzyme Extraction

All steps were carried out at 4°C. Crude protein extracts were prepared by homogenizing freshly excised  
5 stigmata in a chilled mortar in the presence of ice-cold buffer (10:1 (v/w) buffer:tissue) containing 50 mM potassium BisTris, pH 6.9, 10 mM dithiothreitol, 5 mM  $\text{Na}_2\text{S}_2\text{O}_5$ , 1% (w/v) polyvinylpyrrolidone (Sigma, PVP-40) and 10% (v/v) glycerol. The slurry was passed through  
10 miracloth and centrifuged for 10 min at 12,000 g to produce a supernatant that contained the bulk of the LIS activity.

Enzyme Purification

15 The crude extract (100 ml) was loaded onto a DEAE-cellulose (0.7 cm diam. x 6 cm) column (Whatman, DE52) that was pre-equilibrated with a solution containing 50 mM BisTris, pH 6.9, 10% glycerol and 10 mM DTT (buffer A)  
20 at a flow rate of about 1 ml/min. Following elution of the unadsorbed material, the column was washed with 50 ml of buffer A followed by an additional 20 ml of buffer A containing 150 mM KCl. LIS activity was then eluted with 20 ml of buffer A containing 250 mM KCl. Fractions with  
25 the highest LIS activity (about 60% yield, 10 ml), were either pooled and used immediately, or frozen at -20°C for up to 1 month with less than 20 % loss of activity. The DEAE-cellulose purified fractions were diluted 2-fold with ice-cold buffer A, and loaded on a 1 cm diam. x 10  
30 cm hydroxyapatite column (Bio-Gel HT, Bio-Rad, Richmond, CA) installed in a Pharmacia FPLC apparatus, and pre-equilibrated with 100 ml of buffer A, at a flow rate of 0.5 ml/min. After the enzyme was loaded, the column was washed with 20 ml buffer A and then eluted using a linear  
35 gradient (100 ml) from 0 to 200 mM Na-phosphate in buffer A. The fractions containing LIS activity, eluting at

- 54 -

about 100 mM Na-phosphate, were pooled (10 to 16 ml) and loaded on a pre-packed Pharmacia Mono-Q HR 5/5 FPLC column equilibrated with buffer A. After a 20-ml wash with buffer A, a steep linear gradient from 0 to 100 mM KCl in buffer A (10 ml) was applied, followed by a more gradual linear gradient from 100 to 400 mM KCl in buffer A (100 ml, 0.25 ml/min). The enzyme consistently eluted at about 220 mM KCl. After dialysis to assay conditions, the enzyme at this level of purity was used for characterization.

#### Gel Permeation Chromatography and SDS-PAGE

A Superdex 75 Hi Load 16/60 column (Pharmacia FPLC) was employed to determine the native molecular mass of the *C. breweri* linalool synthase. Hydroxyapatite-purified linalool synthase (1 ml, 44.1 pkat/mg protein) was loaded on the Superdex 75 column and eluted with buffer A containing 5 mM DTT, using a flow rate of 1 ml/min. Two-ml fractions were collected. Protein standards of known molecular mass (Sigma, St. Louis, MO) were used for calibration. For SDS-PAGE, the method of Laemmli (Laemmli, 1970) was employed, with 10% acrylamide and a ratio of 30:0.8 w/w acrylamide:bis-acrylamide. Gels were stained with Coomassie Brilliant Blue G (Andrews, 1986) or silver (Blum et al., 1987). The molecular weight marker proteins were from BioRad (Richmond, CA).

#### Enzyme assay

LIS activity was determined by mixing 10  $\mu$ l of the enzyme sample with 12  $\mu$ M [1-<sup>3</sup>H]-GPP (s.a. 150 Ci/mol) in 100  $\mu$ l of assay buffer (50 mM Hepes-KOH, pH 7.8, 10 mM DTT, 5 mM Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub>, 10% (v/v) glycerol, 20 mM MgCl<sub>2</sub> and 5 mM MnCl<sub>2</sub> (Lewinsohn et al., 1991) and, as an overlay to



- 55 -

trap volatiles, either 1 ml hexane (for scintillation counting) or 2 ml of pentane (for radio-GC analysis). The mixture was then vortexed briefly, centrifuged to separate phases (5 sec. Eppendorf) and incubated at 20°C without shaking for up to 1 h (higher temperatures resulted in elevated rates of chemical conversion of GPP to various alcohols, including linalool). After incubation, the assay mixture was briefly mixed again to extract non-polar products into the organic layer. An 800- $\mu$ l aliquot of the hexane phase was placed into a scintillation vial containing 10 ml of a cocktail of 0.4% (w/v) Omnifluor (Du Pont, Boston MA) dissolved in 30% (v/v) ethanol in toluene and counted in a Packard TriCarb 460 CD scintillation spectrometer (efficiency for  $^3\text{H}$ =36%) to determine the total monoterpene synthase activity. To examine in detail the products formed, radio-GC was performed as described (Croteau et al., 1990). For this purpose, the 2 ml pentane extract containing the enzymatically formed  $^3\text{H}$ -labeled products was removed, dried by passage through  $\text{MgSO}_4$ , and internal standards were added (10  $\mu$ g each of linalool and geraniol; nerol was also included in initial experiments). The mixture was then concentrated to ~10  $\mu$ l under a gentle stream of nitrogen, and an aliquot (2-3  $\mu$ l) was injected into a Gow-Mac 550P radio gas chromatograph fitted with a 0.125 in x 12 ft stainless steel column loaded with AT-1000 (Gas Chrom Q, Alltech), attached to a Packard 894 gas proportional counter. The initial column temperature was 170°C and, following a 5 min hold, was programmed at 5°C/min to 220°C, using He at a flow rate of 50 ml/min. Control incubations included the omission of enzyme extract, the use of boiled enzyme extract, the omission of substrate, and the omission of divalent cations. All of these controls produced negligible radioactivity in the hexane phase of the enzyme assay mixtures.

- 56 -

### Protein

Protein was determined by the method of Bradford (Bradford, 1976), using bovine serum albumin as standard.

5

### Stereochemical Analyses

The enantiomeric composition of linalool samples was determined on a fused silica capillary column (0.25 mm internal diam. x 30 m) coated with a 0.25  $\mu$ m film of  $\beta$ -cyclodextrin (J & W Scientific, Cyclodex B), operated at an initial temperature of 75° C for 15 min followed by a rise of 5°C/min to 200° C. H<sub>2</sub> at a head pressure of 13.5 psi was used as carrier gas (Alonso et al., 1992).

15

### Results

Flower stigmata were used as the enzyme source, as they contained very high enzyme activity levels (147 fkat/mg Fr.Wt.) (Pichersky et al., 1994) (See Example 1). A representative purification scheme for the *C. breweri* S-linalool synthase is shown in Table 5. Typically, 10 g Fr.Wt. of freshly excised stigmata gave 140  $\mu$ g of pure linalool synthase following the initial DEAE-cellulose and hydroxyapatite chromatography steps (to remove low molecular weight pigments and phenolic materials that severely interfered with later FPLC steps), and Mono Q chromatography (FIG. 2). SDS-PAGE analysis of many of the purified Mono Q preparations revealed the presence of a single protein band corresponding to a molecular mass of about 79  $\pm$  3 Kda. The N-terminal amino acid sequence of this protein matched the sequence encoded by a LIS cDNA clone. In some preparations, a minor protein band slightly smaller than LIS was also visible (FIG. 2 lanes 3, 4). However, the elution profile of this band from the Mono Q column did not coincide with the peak of LIS

35

- 57 -

activity, and its N-terminal sequence did not match that predicted from the LIS clone. Thus, after attaining a 26-fold purification, accompanied by 9% recovery, a greater than 95% homogeneous preparation was obtained, due in large part to the high specific activity of the starting material and the rapid and gentle fractionation protocol. Only a single peak of linalool synthase activity was observed in each step of the purification.

The native molecular mass of linalool synthase activity was determined to be about  $73 \pm 5$  KDa based on co-elution with bovine serum albumin on gel permeation chromatography and comparison of the elution volume to those of known proteins (FIG. 3). Based on a subunit mass of 79 KDa determined by SDS-PAGE (FIG. 2) and a native molecular size of 73 KDa indicated by gel permeation chromatography (FIG. 3), linalool synthase is thought to be a monomer of  $76 \pm 3$  KDa. Other monoterpene synthases from higher plants are active monomers in the 50-70 KDa range (Alonso, 1992; Lewinsohn et al., 1992b), or homodimers with 40-50 KDa subunits (Gambliel et al., 1984).

Radio-GLC analysis of the products generated by extracts of *C. breweri* stigmata (FIG. 4) or petals that had been incubated with [ $^3$ H]-GPP indicated the presence of linalool only. The preparations were devoid of other monoterpene synthase activities or GPP phosphohydrolase activity as evidenced by the absence of [ $^3$ H]-geraniol in the reaction products. In contrast, *C. breweri* leaves contained only GPP phosphohydrolase activity, as leaf-derived cell-free extracts produced only geraniol. The enantiomer compositions of the linalool emitted by *C. breweri* flowers (obtained by head space collection [Raguso and Pichersky, 1995]), and that produced in vitro from GPP by the purified enzyme from stigmata were next

- 58 -

determined by their separation on a  $\beta$ -cyclodextrin capillary column. Both samples contained only the 3*S*-antipode of linalool.

5           The conversion of GPP to cyclohexanoid monoterpenes is thought to involve an initial ionization step followed by collapse of the resulting ion pair (1) to enzyme-bound LPP, which after *transoid* to *cisoid* rotation, ionizes to promote the cyclization step (FIG. I) (Croteau, 1987).  
10   LPP can serve as an alternate substrate for most monoterpene synthases and is generally more efficient than GPP since the isomerization is commonly the rate-limiting step of the coupled reaction sequence (Croteau et al., 1994; Rajaonarivony et al., 1992). To determine  
15   whether *C. breweri* LIS accepts LPP as an alternate substrate, both the *R*- and the *S*-linalyl enantiomers were tested as precursors (Table 6). Only a low rate of conversion of *S*-LPP to linalool was observed (15% the rate for GPP), whereas the *R*- antipode was essentially  
20   not converted to linalool. This suggests that in the normal reaction the ionization of GPP leads to capture by water of the resulting cation (1) at the tertiary center to give linalool directly without the involvement of LPP. Thus the reaction catalyzed by LIS is considerably  
25   simpler than the coupled isomerization-cyclization sequence catalyzed by monoterpene cyclases (FIG. I).

          Similar to other monoterpene synthases (Alonso, 1992; Lewinsohn et al., 1992; Rajaonarivony et al., 1992;  
30   Alonso et al., 1993), *S*-linalool synthase requires a divalent metal ion for activity.  $Mn^{2+}$  is most efficient ( $K_m=45 \mu M$ ), although  $Mg^{2+}$  ( $K_m= 330 \mu M$ ) can substitute for  $Mn^{2+}$  at half the rate. Neither  $Cu^{2+}$ ,  $Zn^{2+}$ ,  $Ca^{2+}$ , nor  $Co^{2+}$  (at 1 to 10 mM, as the chloride salts) support the  
35   enzymatic reaction, and no detectable linalool is formed in the absence of divalent metal ions.

- 59 -

A  $K_m$  value of 0.9  $\mu$ M was calculated for GPP from a Lineweaver-Burk plot. This value is in the range determined for other monoterpene synthases from plants (Alonso et al., 1992; Alonso et al., 1993). A turnover  
5 number of 31.6  $\text{sec}^{-1}$  was calculated for LIS under saturating conditions, indicating that the enzyme is much faster than other monoterpene synthases examined so far (Alonso et al., 1992; Alonso et al., 1993). A broad pH  
10 optimum of 7.4 was calculated for the enzyme, with the rates at pH 6.4 and 8.4 being ~80% of the optimal. This optimal pH range is similar to those determined for other monoterpene synthases (Alonso et al., 1992; Lewinsohn et al., 1992; Alonso et al., 1993). Similar rates were  
15 observed while substituting Hepes buffer with Tris-HCl. The enzyme is unstable in the absence of DTT (>95% loss over 2 h at 4 °C), and its later addition does not result in the regaining of activity. Addition of the non-ionic  
20 detergent Triton-X-100 (0.1% w/v) had no effect on enzyme activity, but similar levels of sodium dodecyl sulfate resulted in a complete loss of activity. Similarly to other monoterpene synthases (Lewinsohn et al., 1991; Wheeler et al., 1986), the enzyme is very stable to vigorous vortexing in the presence of non-polar organic solvents such as hexane and pentane.

TABLE 5  
Purification of *C. breweri* Linalool Synthase

Purification Step	Protein (mg)	Activity (pkat)	Specific		
			Activity (pkat mg <sup>-1</sup> )	Recovery (%)	Purification Fold
Crude extract <sup>a</sup>	39.6	604	15.2	100	1
DEAE-cellulose	15.4	342	22.2	56.6	1.5
Hydroxyapatite	4.6	203	44.1	33.6	2.9
Mono Q	0.14	59.3	395	9.2	26.0

<sup>a</sup> The starting material was 10 g of excised stigmata (approx. 2500-300 stigmata).

5

10

- 61 -

TABLE 6  
Substrate Specificity of Purified *C. breweri*  
Linalool Synthase

	Substrate <sup>a</sup>	Rate <sup>b</sup>
5	[1- <sup>3</sup> H]Geranyl pyrophosphate	100±9.6
	3R-[1- <sup>3</sup> H]Linalyl pyrophosphate	0.6±0.6
	3S-[1- <sup>3</sup> H]Linalyl pyrophosphate	15.1±6.0

<sup>a</sup> Putative substrates tested at 12μM.

<sup>b</sup> Rates of 100% with [1-<sup>3</sup>H]GPP are relative to 22.  
2pkat/mg protein. Averages and SE's of four  
10 replicate determinations.

While the compositions and methods of this invention have been described in terms of preferred embodiments, it  
15 will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it  
20 will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art  
25 are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

- 62 -

## REFERENCES

- The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
- Alonso, W.R., and Croteau, R. (1993) in *Methods in Plant Biochemistry (Enzymes of Secondary Metabolism)* (Lea, P.J. Ed), pp. 239-260, Academic Press, London.
- Alonso, W.R., Rajaonarivony J.I.M., Gershenzon, J., and Croteau, R. (1992) *J. Biol. Chem.* **267**, 7582-7587.
- An, G., Watson, B.D. and Chiang, C.C. (1992) *Plant Physiol* **81**:301-395.
- Andrews, A.T. (1986) *Electrophoresis: Theory, Techniques and Biochemical and Clinical Applications*, Oxford Univ. Press (Clarendon), London/New York.
- Baskin, T.I., Busby, C.H., Fowke, L.C., Sammut, M., and Gubler, F. (1992) *Planta* **187**:405-413.
- Bevan, M., Barnes, W.M., Chilton, M.D. (1983) *Nucleic Acid Research*. **11**:369-385.
- Blum, H., Beier, H., and Gross, H.J. (1987) *Electrophoresis* **8**, 93-99.
- Bouchez D., Tokuhisa J.G., Llewellyn D.J., Dennis E.S. and Ellis J.G. (1989) *EMBO Journal* **8**(13):4197-4204.
- Bradford, M.M. (1976) *Anal. Biochem.* **72**, 248-254.



- 63 -

- Callis, J., Fromm, M., Walbot, V. (1987) *Genes and Develop.* 1:1183-1200.
- 5 Chandler, V.L., Radicella, J.P., Robbins, P.P., Chen, J.,  
Turks, D. (1989) *The Plant Cell* 1:1175-1183.
- Conkling, M.A., Cheng, C.L., Yamamoto, Y.T., Goodman, H.M. (1990) *Plant Physiol.* 93:1203-1211.
- 10 Cox, K.H., Goldberg, R.B. (1988) In: *Plant Molecular Biology: A Practical Approach*. Shaw, C.H. ed. Oxford:IRL Press, pp 1-35.
- 15 Craig, S., Czaplewski, L.G., Edwards, R.M., Gilbert, R.J., and Hunter, M.G., WO 9313206, July 8, 1993.
- Cristou P., McCabe D.E., Swain W.F. (1988) *Plant Physiol* 87:671-674.
- 20 Croteau, R., Alonso, W.R., Koepp, A.E., and Johnson, M.A. (1994) *Arch. Biochem. Biophys.* 309, 184-192.
- 25 Croteau R, Satterwhite DM (1990) Methods for radio-capillary gas chromatography employing a modified oxidation-reductive train and flow-through detector. *J Chromatogr* 500: 349-354.
- Croteau, R. (1987) *Chem. Rev.* 87, 929-954.
- 30 Croteau R, Cane DE (1985) Monoterpenes and sesquiterpene cyclases. *Meth Enzymol* 110: 383-405.
- 35 Croteau R, Karp F (1991) Origin of Natural Odorants. Ch. 4, pp 101-126 in Muller P, Lamparsky D, eds, "Perfume: art, science and technology", Elsevier Appl Sci, Inc. NY.

- 64 -

- 5 Croteau R (1986) Biochemistry of monoterpenes and  
sesquiterpenes of the essential oils. In Herbs, Spices  
and Medicinal Plants; Recent Advances in Botany,  
Horticulture and Pharmacology (Cracker LE, Simon JE, eds)  
vol 1, Oryx Press, Phoenix, p 81-133.
- Dawson, F.A. (1994) *Naval Stores Review*, March/April, 6-  
12.
- 10 Dobson HEM (1993) Floral Volatiles in Insect Biology. in  
Bernays E (ed) *Insect-Plant Interactions*, Vol V. pp 47-  
81. CRC Press, Boca Raton.
- 15 Dobson HEM, Bergstrom G, Groth I (1990) Differences in  
fragrance chemistry between flower parts of *Rosa rugosa*  
Thunb. (Rosaceae). *Israel J Bot* 39:143-156.
- Dodson C, Dressler R, Hills H, Adams R, Williams N (1969)  
Biologically active compounds in orchid fragrances.  
20 *Science* 164: 1243-1249.
- Ebert, P.R., Ha, S.B., An. G. (1987) *PNAS* 84:5745-5749.
- 25 Ellis J.G., Llewellyn D.J., Walker J.C., Dennis E.S., and  
Peacock W.J. (1987) *EMBO Journal* 6(11):3203-3208.
- Forde, B.G. (1994) *Results Probl Cell Differ.* 20:87-103.
- 30 Fromm, H., Katagiri, F., Chua, N.H. (1989) *The Plant Cell*  
1:977-984.
- Galen C (1985) Regulation of seed set in *Polemonium*  
*viscosum*: floral scents, pollination and resources.  
35 *Ecology* 66: 792-797.

- 65 -

- Galen C, Kevan P (1983) Bumblebee foraging and floral scent dimorphism: *Bombus kirbyellus* and *Polemonium viscosum*. *Canad J Zool* 61: 1207-1213.
- 5 Gallie, D.R., Lucas, W.J., Walbot, V. (1989) *The Plant Cell* 1:301-311.
- Gambliel H, Croteau R (1982) Biosynthesis of ( $\pm$ )- $\alpha$ -pinene and ( $\pm$ )- $\beta$ -pinene from geranyl pyrophosphate by a soluble  
10 enzyme system from sage (*Salvia officinalis*). *J Biol Chem* 257: 2335-2342.
- Gambliel, H., and Croteau, R. (1984) *J. Biol. Chem.* 259, 740-748.  
15
- Gelvin, S.B., Schilperoort, R.A., Varma, D.P.S., eds. *Plant Molecular Biology Manual* (1990).
- Gershenzon J, Croteau R (1993) Terpenoid biosynthesis:  
20 the basic pathway and formation of monoterpenes, sesquiterpenes, and diterpenes. In Moore Jr TS (ed) *Lipid metabolism in Plants*. CRC Press, Boca Raton FL pp 339-388.
- 25 Gijzen, M., Lewinsohn, E., Savage, T.J. and Croteau, R.B. (1993) in *Bioactive Volatile Compounds from Plants*. (Teranishi, R., Buttery, R.J. and Sugisawa, H. Eds.) pp. 8-22. ACS Symposium Series 525. Washington DC.
- 30 Giuliano, G., Hoffman, N.E., Ko, K., Scolnik, P.A., Cashmore, A.R. (1988) *EMBO J.* 7:3635-3642.
- Harborne J.B. (1991) in *Ecological Chemistry and Biochemistry of Plant Terpenoids* (Harborne J.B., Tomes-  
35 Barberan F.A. Eds.) pp. 399-426, Clarendon Press, London.

- 66 -

- Hemleben, V., and Zentgraph, U. (1994) *Results Probl Cell Differ.* 20:3-24.
- Hudspeth, R.L. and J.W.Grula. (1989) *Plant Mol. Biol.*  
5 12:579-589.
- Jefferson, R.A. (1987) *Plant Mol Biol Rep* 5:387-405.
- Joulain D (1987) The composition of the headspace from  
10 fragrant flowers: further results. *Flavour and Fragrances J* 2: 149-155.
- Kaiser R (1991) Trapping, investigation and  
reconstitution of flower scents. Ch 7, pp 213-248 in  
15 Muller P, Lamparsky D (eds), "Perfume: Art, Science and  
Technology", Elsevier Appl Sci, Inc, NY.
- Kellmann, J.W., Pichersky, E., Piechulla, B., (1990)  
Photobiology and Photochemistry 52:35-41.  
20
- Kellmann J., Wiese, M., Pichersky, E., Piechulla, B.  
(1993) *Mol Gen Genet* 237:439-448.
- Knudsen, J.T., and Tollsten, L. (1993) *Bot. J. Linn. Soc.*  
25 113, 263-284.
- Knudsen JT, Tollsten L (1991) Floral scent and  
intrafloral scent differentiation in *Moneses* and *Pyrola*.  
(Pyrolaceae). *Plant Syst Evol* 177: 81-91.  
30
- Knudsen JT, Tollsten L, Bergstrom G (1993) Floral scents  
- a checklist of volatile compounds isolated by head-  
space techniques. *Phytochemistry* 33: 253-280.
- 35 Kyte, J. and Doolittle, R.F. (1982) *J. Mol. Biol.*,  
157(1):105-132.

- 67 -

Laemmli, U.K. (1970) *Nature (London)* **227**, 680-685.

Langenheim, J.H. (1994) *J. Chem. Ecol.* **20**, 1223-1280.

- 5    Lawton, M.A., Tierney, M.A., Nakamura, I., Anderson, E.,  
     Komeda, Y., Dube, P., Hoffman, N., Fraley, R.T., Beachy,  
     R.N. (1987) *Plant Mol. Biol.* **9**:315-324.
- 10    Lewinsohn, E., Gijzen, M. and Croteau, R.B. (1992) in  
     Regulation of Isopentenoid Metabolism (Nes, W.D., Parish,  
     E.J. and Trzaskos, J.M. Eds.) pp. 8-17, ACS Symposium  
     Series 497. Washington DC. .
- 15    Lewinsohn E, Gijzen M, Croteau R (1992) Wound-inducible  
     pinene cyclases from grand fir: purification,  
     characterization and renaturation after SDS-PAGE. *Arch*  
     *Biochem Biophys* **293**: 167-173.
- 20    Lewinsohn E, Gijzen M, Savage TJ, Croteau R (1991)  
     Defense mechanisms in conifers. Relationship of  
     monoterpene cyclase activity to anatomical specialization  
     and oleoresin monoterpene content. *Plant Physiol* **96**: 38-  
     43.
- 25    Loughrin J, Hamilton-Kemp T, Burton HR, Andersen RA,  
     Hildebrand DF (1992) Glycosidically bound volatile  
     components of *Nicotiana sylvestris* and *N. suaveolens*  
     flowers. *Phytochemistry* **31**: 1537-1540.
- 30    Loughrin J, Hamilton-Kemp T, Andersen RA, Hildebrand DF  
     (1990) Volatiles from flowers of *Nicotiana sylvestris*, *N.*  
     *otophora* and *Malus X domestica*: headspace components and  
     day/night changes in their relative concentrations.  
     *Phytochemistry* **29**: 2473-2477.

35

- 68 -

- Loughrin J, Hamilton-Kemp T, Andersen R, Hildebrand D  
(1991) Circadian rhythm of volatile emission from flowers  
of *Nicotiana sylvestris* and *N. suaveolens*. *Physiol Plant*  
83: 492-496.
- 5
- MacSwain J, Raven P, Thorp R (1973) Comparative behavior  
of bees and Onagraceae. IV. *Clarkia* bees of the western  
United States. *Univ of Calif Publ Ent* 70: 1-80.
- 10
- Matile P, Altenburger R (1988) Rhythms of fragrance  
emission in flowers. *Planta* 174: 242-247.
- McGrath, J.M., Hickok, L., Pichersky, E. (1993) *Plant*  
*Syst Evol* 189:203-210.
- 15
- McGrath, J.M., Jansco M., Pichersky, E. (1993) *Theor Appl*  
*Genet* 86:880-888.
- Nagai, K., Thogersen, H.C. (1987) *Methods in Enzymology*  
20 153:461-481.
- Odell, J.T., Nagy, F., Chua, N.H. (1985) *Nature* 313:810-  
812.
- 25
- Omirulleh, S, Abraham, M., Golovkin, M., Stefanov, I.,  
Karabaev, M.K., Mustardy, L., Morocz, S., Dudits, D.  
(1993) *Plant Molecular Biology* 21:415-428.
- Overland L (1960) Endogenous rhythm in opening and odor  
30 of the flowers of *Cestrum nocturnum*. *Am J Bot* 47: 378-  
382.
- Pellmyr O (1986) Three pollination morphs in *Cimicifuga*  
simplex: incipient speciation due to inferiority in  
35 competition. *Oecologia* 78: 304-307.

- 69 -

- Pichersky, E., Raguso, R.A., Lewinsohn, E., and Croteau, R. (1994) *Plant Physiol.* 106:1533-1540.
- 5 Pichersky, E., Logsdon, J., McGrath, J.M., Stasys, R.A. (1991) *Mol Gen Genet* 225:453-458.
- Pichersky, E., Brock, T.G., Nguyen, D., Hoffman, N.E., Piechulla, B., Tanksley, S.D., Green, B. (1989) *Plant Mol Biol* 12:257-270.
- 10 Pichersky, E., Tanksley, S.D., Piechulla B., Stayton, M.M., Dunsmuir, P. (1988) *Plant Mol Biol* 11:69-71.
- Pichersky, E., Hoffman, N.E., Malik, V.S., Bernatzky, R., Tanksley, S.D., Szabo, L., Cashmore, A.R. (1987) *Plant Mol Biol* 9:109-120.
- 15 Pichersky, E., Hoffman, N.E., Bernatzky, R., Piechulla, B., Tanksley, S.D., Cashmore, A.R. (1987) *Plant Mol Biol* 9:205-216.
- 20 Piechulla, B., Kellmann, J., Pichersky, E., Schwartz, E., Forster, H.H., (1991) *Mol Gen Genet* 230:413-422.
- 25 Raguso RA, Pichersky E (1995) Floral volatiles from *Clarkia breweri* and *C. concinna* (Onagraceae): recent evolution of floral scent and moth pollination. *Plant Sys Evol*, 194:55-67.
- 30 Rajaonarivony JIM, Gershenzon J, Croteau R (1992) Characterization and mechanism of (4S)-limonene synthase, a monoterpene cyclase from the glandular trichomes of peppermint (*Mentha X piperita*). *Arch Biochem Biophys* 296: 49-57.
- 35

- 70 -

- Rajaonarivony, J.I.M, Gershenzon, J., and Croteau, R.  
(1992) *Arch. Biochem. Biophys.* 296, 49-57.
- Sambrook, J., Fritsch, E.F., and Maniatus, T. (1989)  
5 Molecular Cloning, A Laboratory Manual 2nd ed.
- Stern W, Curry K, Pridgeon A (1987) Osmophores of  
*Stanhopea* (Orchidaceae). *Am J Bot* 74: 1323-1331.
- 10 Studier, F.W., Rosenberg, A.H., Dunn, J.J. (1990) Methods  
in Enzymology 185:60-89.
- Sullivan, T. et al. (1989) *Mol. Gen. Genet* 215:431-440.
- 15 Tabor, S., Richardson, C.C. (1985) *Proc Natl Acad Sci*  
(USA) 82:1074-1078.
- Turlings, T.C.J., Tumlinson, J.H. (1992) *Proc Natl Acad*  
*Sci (USA)* 89:8399-8402.
- 20 Turlings, T.C.J., Tumlinson, J.H., and Lewis, W.J. (1990)  
*Science* 250, 1251-1253.
- Vasil, V., Clancy, M., Ferl, R.J., Vasil, I.K., Hannah,  
25 L.C. (1989) *Plant Physiol.* 91:1575-1579.
- Walker, J.C., Howard, E.A., Dennis, E.S., Peacock, W.J.  
(1987) *PNAS* 84:6624-6628.
- 30 Wang, Y., Zhang, W., Cao, J., McEhoy, D. and Ray Wu.  
(1992) *Molecular and Cellular Biology* 12:3399-3406.
- Watanabe N, Watanabe S, Nakajima R, Moon JH, Shimokihira  
K, Inagaki J, Etoh H, Asai T, Sakata K, Ina K (1993)  
35 Formation of flower fragrance compounds from their



- 71 -

precursors by enzymic action during flower opening.  
Biosci Biotech Biochem 57: 1101-1106.

- 5 Wheeler, C.J., and Croteau, R. (1986) *Arch. Biochem. Biophys.* 248, 429-434.

Wilmink A; van de Ven BC; Dons JJ. (1995) *Plant Mol Biol* (NETHERLANDS) 28, 949-55.

- 10 Winterhalter, P., Katzenberger, D., and Schreier, P. (1986) *Phytochemistry* 25, 1347-1350.

- 15 Winterhalter P, Katzenberger D, Schreier P (1986) 6,7-epoxy-linalool and related oxygenated terpenoids from *Carica papaya* fruit. *Phytochemistry* 25: 1347-1350.

Yang, N.S., Russell, D. (1990) *PNAS* 87:4144-4148.

- 72 -

## SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT:

(A) NAME: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

(B) STREET: Wolverine Tower, Room 2071  
3003 South State Street

10 (C) CITY: Ann Arbor

(D) STATE: Michigan

(E) COUNTRY: United States of America

(F) POSTAL CODE (ZIP): 48109-1280

15 (ii) TITLE OF INVENTION: USE OF LINALOOL SYNTHASE IN  
GENETIC ENGINEERING OF  
SCENT PRODUCTION

(iii) NUMBER OF SEQUENCES: 2

20

**(iv) COMPUTER READABLE FORM:**

(A) MEDIUM TYPE: Floppy disk

**(B) COMPUTER: IBM PC compatible**

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

25 (D) SOFTWARE: PatentIn Release #1.0, Version  
#1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/005,146

30 (B) FILING DATE: 12-OCT-1995

(2) INFORMATION FOR SEQ ID NO: 1:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2681 base pairs

-73-

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## 5 (ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION: 28..2637

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

10

AACCAAACCA CCTTAAACAA GACAACC ATG CAG CTC ATA ACA AAT TTC TCC 51

Met Gln Leu Ile Thr Asn Phe Ser

1 5

15 TCA TCA TCA TCA GAA TTG CAG TTT CTT GTG GAT AAG GTT AAG AGA GAA 99

S r Ser Ser Glu Leu Gln Phe Leu Val Asp Lys Val Lys Arg Glu

10 15 20

TCA TTG TCT TCT TCA TCA TCT AAT ACT CAG AAT TTG TTT CTC TCA ACT 147

20 Ser Leu Ser Ser Ser Ser Asn Thr Gln Asn Leu Phe Leu Ser Thr

25 30 35 40

-74-

TCA CCT TAT GAC ACT GCT TGG CTC GCC CTT ATC CCT CAT CCT CAT CAT 195  
 Ser Pro Tyr Asp Thr Ala Trp Leu Ala Leu Ile Pro His Pro His His  
 45 50 55

5 CAC CAT CAC CAT GGC CGA CCC ATG TTT GAA AAA TGT CTG CAA TGG ATT 243  
 His His His His Gly Arg Pro Met Phe Glu Lys Cys Leu Gln Trp Ile  
 60 65 70

CTC CAT AAC CAG ACA CCA GGT TTC TGG GCA GCA GCT GGT GAC AAT 291  
 10 Leu His Asn Gln Thr Pro Gln Gly Phe Trp Ala Ala Ala Gly Asp Asn  
 75 80 85

ATT TCC GAC ACC GAC GAT GAC GTC ACC CTG GAT TGT CTT CTA TCA ACC 339  
 Ile Ser Asp Thr Asp Asp Val Thr Leu Asp Cys Leu Leu Ser Thr  
 15 90 95 100

TTG GCT TGC TTA GTT GCA CTC AAA AGG TGG CAG CTT GCT CCC GAC ATG 387  
 Leu Ala Cys Leu Val Ala Leu Lys Arg Trp Gln Leu Ala Pro Asp Met  
 105 110 115 120

ATT CAT AAA GGA TTG GAA TTT GTA AAT AGA AAC ACA GAG AGA CTT GTA 435  
 Ile His Lys Gly Leu Glu Phe Val Asn Arg Asn Thr Glu Arg Leu Val  
 125 130 135

-75-

483

ATG AAG CAG AAG CCG AGC GAC GTT CCT CGT TGG TTC ACC ATC ATG TTC  
 Met Lys Gln Lys Pro Ser Asp Val Pro Arg Trp Phe Thr Ile Met Phe  
 140 145 150

531

CCG GCG ATG CTC GAG CTT GCC GGC GCT TCC AGT CTC CGA GTC GAT TTC  
 Pro Ala Met Leu Glu Leu Ala Gly Ala Ser Ser Leu Arg Val Asp Phe  
 155 160 165

579

AGC GAG AAT CTT AAC AGA ATC TTG GTG GAA CTA TCT CAA AAT AGG GAT  
 Ser Glu Asn Leu Asn Arg Ile Leu Val Glu Leu Ser Gln Asn Arg Asp  
 170 175 180

627

GAC ATT CTC ACA AGG GAG GAA GTT GAT GAG AAG AAG CAA TAC TCA CCA  
 Asp Ile Leu Thr Arg Glu Glu Val Asp Glu Lys Lys Gln Tyr Ser Pro  
 185 190 195 200

675

TTG CTA CTA TTT CTA GAA GCA TTG CCT GCA CAA TCC TAT GAC AAT GAT  
 Leu Leu Leu Phe Leu Glu Ala Leu Pro Ala Gln Ser Tyr Asp Asn Asp  
 205 210 215

723

GTT CTA AAG CAA ATT ATA GAC AAG AAC TTG AGC AAT GAT GGT TCT TTA  
 Val Leu Lys Gln Ile Ile Asp Lys Asn Leu Ser Asn Asp Gly Ser Leu  
 220 225 230

-76-

TTG CAA TCG CCT TCT GCT ACA GCA AGA GCA TAC ATG ATA ACA GGA AAT 771  
 Leu Gln Ser Pro Ser Ala Thr Ala Arg Ala Tyr Met Ile Thr Gly Asn  
 235 240 245

5 ACC AGA TGC TTA TCG TAT CTA CAC TCT TTA ACA AAT AGC TGC TCT AAT 819  
 Thr Arg Cys Leu Ser Tyr Leu His Ser Leu Thr Asn Ser Cys Ser Asn  
 250 255 260

GGA GGA GTA CCA TCA TTC TAT CCT GTT GAC GAC GAC CTC CAT GAT CTT 867  
 Gly Gly Val Pro Ser Phe Tyr Pro Val Asp Asp Leu His Asp Leu  
 265 270 275 280

GTC ATG GTG AAT CAA CTG ACA AGG TCG GGT TTG ACT GAA CAT CTC ATC 915  
 Val Met Val Asn Gln Leu Thr Arg Ser Gly Leu Thr Glu His Leu Ile  
 285 290 295

CCG GAG ATT GAC CAC CTT CTA CTC AAA GTT CAA AAG AAC TAC AAA TAC 963  
 Pro Glu Ile Asp His Leu Leu Leu Lys Val Gln Lys Asn Tyr Lys Tyr  
 300 305 310

20 AAA AAG CAT CAC CAA AAT CAT TGT ATA GCA TTG CTG CGG AAC TAT ACG 1011  
 Lys Lys His His Gln Asn His Cys Ile Ala Leu Leu Arg Asn Tyr Thr  
 315 320 325

-77-

1059  
 GGA TTC ATT AGC ATT TTT GGT TGC TTC GAG TCA ATA ATC ACT GGG TAT  
 Gly Phe Ile Ser Ile Phe Gly Cys Phe Glu Ser Ile Ile Thr Gly Tyr  
 330 335 340

1107  
 5 CAC CAT CAA TTT TTT TGT TGG TTT TTA GAT GAC GAC GAA ATC CGT GAT  
 His His Gln Phe Phe Cys Trp Phe Leu Asp Asp Glu Ile Arg Asp  
 345 350 355 360

1155  
 CAC ATC GAA ACA AAC TAC GAG GAA TTT GCT GCC GTG CTT CTT AAT GTG  
 10 His Ile Glu Thr Asn Tyr Glu Glu Phe Ala Ala Val Leu Leu Asn Val  
 365 370 375

1203  
 TAT CGA GCT ACC GAT CTT ATG TTC TCC GGC GAA GTC CAA CTT GTC GAA  
 Tyr Arg Ala Thr Asp Leu Met Phe Ser Gly Glu Val Gln Leu Val Glu  
 15 380 385 390

1251  
 GCA AGA TCT TTC GCT ACC AAG AAT CTT GAG AAA ATA TTA GCA ACA GGA  
 Ala Arg Ser Phe Ala Thr Lys Asn Leu Glu Lys Ile Leu Ala Thr Gly  
 395 400 405

1299  
 AAC ATA CAT AAA ACT AAT GCA GAT ATC TCA TCT AGT TTG CAT AAG ATG  
 Asn Ile His Lys Thr Asn Ala Asp Ile Ser Ser Ser Leu His Lys Met  
 410 415 420

20

- 78 -

	ATC GAA CAC GAA CTA AGA GTT CCT TGG ACC GCA AGA ATG GAC CAT GTT	1347
	Ile Glu His Glu Leu Arg Val Pro Trp Thr Ala Arg Met Asp His Val	
	425 430 435 440	
5	GAA AAT CGA ATT TGG ATC GAA GAA ATA GCT TCC AGT GCT TTA TGG TTT	1395
	Glu Asn Arg Ile Trp Ile Glu Glu Ile Ala Ser Ser Ala Leu Trp Phe	
	445 450 455	
	GGA AAA TCA TCC ATC CTT AGG TTA TCT TGC TTT CAC AAG ATG AGT TTA	1443
10	Gly Lys Ser Ser Ile Leu Arg Leu Ser Cys Phe His Lys Met Ser Leu	
	460 465 470	
	CAG CAA CTC GCG GTG AAA AAT TAT ACG CTT CGA CAA TTG GTT TAC CGA	1491
	Gln Gln Leu Ala Val Lys Asn Tyr Thr Leu Arg Gln Leu Val Tyr Arg	
15	475 480 485	
	GAC GAG CTT GCG GAA GTT GAG AGG TGG TCT AAA GAA AGA GGG CTA TGT	1539
	Asp Glu Leu Ala Glu Val Glu Arg Trp Ser Lys Glu Arg Gly Leu Cys	
	490 495 500	
20	GAC ATG GGA TTT TGT AGA GAG AAA ACC GGG TAT TGT TAC TAC GCA TTT	1587
	Asp Met Gly Phe Cys Arg Glu Lys Thr Gly Tyr Cys Tyr Tyr Ala Phe	
	505 510 515 520	



-79-

GCG GCA AGT ACT TGT CTG CCG TGG AGT TCC GAC GTG AGG CTG GTC CTG 1635  
Ala Ala Ser Thr Cys Leu Pro Trp Ser Ser Asp Val Arg Leu Val Leu 535  
525 530

ACC AAG GCG GCA GTT GTC ATT ACA GTG GCC GAT GAT TTC TTT GAT GTC 1683  
Thr Lys Ala Ala Val Val Ile Thr Val Ala Asp Asp Phe Phe Asp Val 550  
540 545

GAA GGA TCT ATG GTT GAT CTC GAA AAA TTA ACG GAT GCA GTT CGG AGG 1731  
Glu Gly Ser Met Val Asp Leu Glu Lys Leu Thr Asp Ala Val Arg Arg 565  
555 560

TGG GAT GCG GAA GGG TTA GGC AGC CAC AGC AAG ACA ATA TTT GAA GCC 1779  
Trp Asp Ala Glu Gly Leu Gly Ser His Ser Lys Thr Ile Phe Glu Ala 580  
570 575

CTG GAT GAT CTT GTA AAT GAA GTT AGA CTC AAG TGT TTC CAA CAA AAT 1827  
Leu Asp Asp Leu Val Val Asn Glu Val Arg Leu Lys Cys Phe Gln Gln Asn 600  
585 590 595

GGA CAA GAC ATC AAA AAC AAT CTC CAA CAA TTA TGG TAT GAA ACA TTC 1875  
Gly Gln Asp Ile Lys Asn Asn Leu Gln Gln Leu Trp Tyr Glu Thr Phe 615  
605 610

- 80 -

1923

CAT TCA TGG CTT ATG GAA GCT AAG TGG GGA AAG GGG TTA ACA AGT AAA  
 His Ser Trp Leu Met Glu Ala Lys Trp Gly Lys Gly Leu Thr Ser Lys  
 620 625 630

1971

CCA TCT GTA GAT GTG TAT CTT GGA AAT GCA ATG ACA TCC ATA GCA GCT  
 Pro Ser Val Asp Val Tyr Leu Gly Asn Ala Met Thr Ser Ile Ala Ala  
 635 640 645

2019

CAC ACC ATG GTC CTT ACA GCA TCC TGT CTT CTA GGT CCC GGT TTC CCG  
 His Thr Met Val Leu Thr Ala Ser Cys Leu Gly Pro Gly Phe Pro  
 650 655 660

2067

GTT CAC CAA CTA TGG TCG CAA AGG CGC CAC CAG GAC ATT ACA TCC TTG  
 Val His Gln Leu Trp Ser Gln Arg Arg His Gln Asp Ile Thr Ser Leu  
 665 670 675 680

2115

CTC ATG GTC TTG ACT CGC TTG CTA AAT GAC ATT CAA TCC TAC TTG AAA  
 Leu Met Val Leu Thr Arg Leu Leu Asn Asp Ile Gln Ser Tyr Leu Lys  
 685 690 695

20

GAA GAA GAC GAA GGA AAA ATA AAC TAT GTA TGG ATG TAC ATG ATC GAG  
 Glu Glu Asp Glu Gly Lys Ile Asn Tyr Val Trp Met Tyr Met Ile Glu  
 700 705 710

-81-

AAC AAT CAA GCG TCG ATA GAT GAC TCG GTT CGA CAC GTC CAG ACG ATA 2211  
 Asn Asn Gln Ala Ser Ile Asp Asp Ser Val Arg His Val Gln Thr Ile  
 715 720 725

5 ATC AAT GTA AAA AAG CAA GAA TTC ATC CAA CGT GTT CTA TCG GAT CAA 2259  
 Ile Asn Val Lys Lys Gln Glu Phe Ile Gln Arg Val Leu Ser Asp Gln  
 730 735 740

CAT TGC AAT CTC CCA AAG TCA TTC AAG CAG CTC CAT TTC TCC TGC CTC 2307  
 10 His Cys Asn Leu Pro Lys Ser Phe Lys Gln Leu His Phe Ser Cys Leu  
 745 750 755 760

AAA GTA TTC AAC ATG TTC TTC AAC TCC TCC AAC ATT TTC GAC ACT GAT 2355  
 Lys Val Phe Asn Met Phe Phe Asn Ser Ser Asn Ile Phe Asp Thr Asp  
 15 765 770 775

ACC GAC CTT CTT CTT GAC ATT CAC GAA GCT TTT GTT TCT CCA CCA CAA 2403  
 Thr Asp Leu Leu Leu Asp Ile His Glu Ala Phe Val Ser Pro Pro Gln  
 780 785 790

GTT CCC AAA TTC AAA CCC CAC ATC AAG CCA CCT CAT CAG CTT CCA GCA 2451  
 Val Pro Lys Phe Lys Pro His Ile Lys Pro Pro His Gln Leu Pro Ala  
 795 800 805

-82-

ACA CTT CAG CCA CCT CAT CAG CCC CAA CAA ATA ATG GTC AAT AAG AAG 2499  
 Thr Leu Gln Pro Pro His Gln Pro Gln Ile Met Val Asn Lys Lys  
 810 815 820

5 AAG GTG GAA ATG GTT TAC AAA AGC TAT CAT CAT CCA TTC AAG GTT TTC 2547  
 Lys Val Glu Met Val Tyr Lys Ser Tyr His His Pro Phe Lys Val Phe  
 825 830 835 840

ACC TTG CAG AAG AAA CAA AGT TCG GGA CAT GGT ACA ATG AAT CCA AGG 2595  
 Thr Leu Gln Lys Lys Gln Ser Ser Gly His Gly Thr Met Asn Pro Arg  
 845 850 855

GCT AGT ATC TTA GCA GGA CCC AAC ATC AAA CTA TGT TTC AGT 2637  
 Ala Ser Ile Leu Ala Gly Pro Asn Ile Lys Leu Cys Phe Ser  
 860 865 870

15 TAACGAATAC ACTACCTTGT TATTAGAAGA TGTCACCAGT TTCC 2681

20 (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 870 amino acids

- 83 -

(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

1	Met	Gln	Leu	Ile	Thr	Asn	Phe	Ser	Ser	Ser	Ser	Glu	Leu	Gln	Phe	15
10	Leu	Val	Asp	Lys	Val	Lys	Arg	Glu	Ser	Leu	Ser	Ser	Ser	Ser	Asn	30
	Thr	Gln	Asn	Leu	Phe	Leu	Ser	Thr	Ser	Pro	Tyr	Asp	Thr	Ala	Trp	Leu
15	Ala	Leu	Ile	Pro	His	Pro	His	His	His	His	His	Gly	Arg	Pro	Met	45
	Phe	Glu	Lys	Cys	Leu	Gln	Trp	Ile	Leu	His	Asn	Gln	Thr	Pro	Gln	Gly
20																80
	Phe	Trp	Ala	Ala	Ala	Gly	Asp	Asn	Ile	Ser	Asp	Thr	Asp	Asp	Val	95

- 84 -

Thr Leu Asp Cys Leu Leu Ser Thr Leu Ala Cys Leu Val Ala Leu Lys  
 100 105 110

Arg Trp Gln Leu Ala Pro Asp Met Ile His Lys Gly Leu Glu Phe Val  
 5 115 120 125

Asn Arg Asn Thr Glu Arg Leu Val Met Lys Gln Lys Pro Ser Asp Val  
 130 135 140

10 Pro Arg Trp Phe Thr Ile Met Phe Pro Ala Met Leu Glu Leu Ala Gly  
 145 150 155 160

Ala Ser Ser Leu Arg Val Asp Phe Ser Glu Asn Leu Asn Arg Ile Leu  
 165 170 175

15 Val Glu Leu Ser Gln Asn Arg Asp Asp Ile Leu Thr Arg Glu Glu Val  
 180 185 190

Asp Glu Lys Lys Gln Tyr Ser Pro Leu Leu Leu Phe Leu Glu Ala Leu  
 20 195 200 205

Pro Ala Gln Ser Tyr Asp Asn Asp Val Leu Lys Gln Ile Ile Asp Lys  
 210 215 220

- 85 -

Asn Leu Ser Asn Asp Gly Ser Leu Leu Gln Ser Pro Ser Ala Thr Ala  
225 230 235 240

Arg Ala Tyr Met Ile Thr Gly Asn Thr Arg Cys Leu Ser Tyr Leu His  
245 250 255

5

Ser Leu Thr Asn Ser Cys Ser Asn Gly Gly Val Pro Ser Phe Tyr Pro  
260 265 270

10 Val Asp Asp Asp Leu His Asp Leu Val Met Val Asn Gln Leu Thr Arg  
275 280 285

Ser Gly Leu Thr Glu His Leu Ile Pro Glu Ile Asp His Leu Leu Leu  
290 295 300

15

Lys Val Gln Lys Asn Tyr Lys Tyr Lys Lys His His Gln Asn His Cys  
305 310 315 320

Ile Ala Leu Leu Arg Asn Tyr Thr Gly Phe Ile Ser Ile Phe Gly Cys  
325 330 335

20

Phe Glu Ser Ile Ile Thr Gly Tyr His His Gln Phe Phe Cys Trp Phe  
340 345 350

- 86 -

Leu Asp Asp Asp Glu Ile Arg Asp His Ile Glu Thr Asn Tyr Glu Glu  
 355 360 365

Phe Ala Ala Val Leu Leu Asn Val Tyr Arg Ala Thr Asp Leu Met Phe  
 370 375 380

Ser Gly Glu Val Gln Leu Val Glu Ala Arg Ser Phe Ala Thr Lys Asn  
 385 390 395 400

10 Leu Glu Lys Ile Leu Ala Thr Gly Asn Ile His Lys Thr Asn Ala Asp  
 405 410 415

Ile Ser Ser Ser Leu His Lys Met Ile Glu His Glu Leu Arg Val Pro  
 420 425 430

15 Trp Thr Ala Arg Met Asp His Val Glu Asn Arg Ile Trp Ile Glu Glu  
 435 440 445

Ile Ala Ser Ser Ala Leu Trp Phe Gly Lys Ser Ser Ile Leu Arg Leu  
 450 455 460

Ser Cys Phe His Lys Met Ser Leu Gln Gln Leu Ala Val Lys Asn Tyr  
 465 470 475 480



Thr Leu Arg Gln Leu Val Tyr Arg Asp Glu Leu Ala Glu Val Glu Arg  
485 490 495

5 Trp Ser Lys Glu Arg Gly Leu Cys Asp Met Gly Phe Cys Arg Glu Lys  
500 505 510

Thr Gly Tyr Cys Tyr Tyr Ala Phe Ala Ala Ser Thr Cys Leu Pro Trp  
515 520 525

10 Ser Ser Asp Val Arg Leu Val Leu Thr Lys Ala Ala Val Val Ile Thr  
530 535 540

Val Ala Asp Asp Phe Phe Asp Val Glu Gly Ser Met Val Asp Leu Glu  
545 550 555 560

15 Lys Leu Thr Asp Ala Val Arg Arg Trp Asp Ala Glu Gly Leu Gly Ser  
565 570 575

20 His Ser Lys Thr Ile Phe Glu Ala Leu Asp Asp Leu Val Asn Glu Val  
580 585 590

Arg Leu Lys Cys Phe Gln Gln Asn Gly Gln Asp Ile Lys Asn Asn Leu  
595 600 605

	Gln Gln Leu Trp Tyr Glu Thr Phe His Ser Trp Leu Met Glu Ala Lys	
	610	615 620
5	Trp Gly Lys Gly Leu Thr Ser Lys Pro Ser Val Asp Val Tyr Leu Gly	
	625	630 635 640
	Asn Ala Met Thr Ser Ile Ala Ala His Thr Met Val Leu Thr Ala Ser	
	645	650 655
10	Cys L u Leu Gly Pro Gly Phe Pro Val His Gln Leu Trp Ser Gln Arg	
	660	665 670
	Arg His Gln Asp Ile Thr Ser Leu Leu Met Val Leu Thr Arg Leu Leu	
	675	680 685
15	Asn Asp Ile Gln Ser Tyr Leu Lys Glu Glu Asp Glu Gly Lys Ile Asn	
	690	695 700
20	Tyr Val Trp Met Tyr Met Ile Glu Asn Asn Gln Ala Ser Ile Asp Asp	
	705	710 715 720
	Ser Val Arg His Val Gln Thr Ile Ile Asn Val Lys Lys Gln Glu Phe	
	725	730 735

Ile Gln Arg Val Leu Ser Asp Gln His Cys Asn Leu Pro Lys Ser Phe  
740 745 750

Lys Gln Leu His Phe Ser Cys Leu Lys Val Phe Asn Met Phe Phe Asn  
755 760 765

Ser Ser Asn Ile Phe Asp Thr Asp Thr Asp Leu Leu Asp Ile His  
770 775 780

10 Glu Ala Phe Val Ser Pro Pro Gln Val Pro Lys Phe Lys Pro His Ile  
785 790 795 800

Lys Pro Pro His Gln Leu Pro Ala Thr Leu Gln Pro Pro His Gln Pro  
805 810 815

15 Gln Gln Ile Met Val Asn Lys Lys Lys Val Glu Met Val Tyr Lys Ser  
820 825 830

20 Tyr His His Pro Phe Lys Val Phe Thr Leu Gln Lys Lys Gln Ser Ser  
835 840 845

Gly His Gly Thr Met Asn Pro Arg Ala Ser Ile Leu Ala Gly Pro Asn  
850 855 860

Ile Lys Leu Cys Phe Ser  
865 870

- 35
- heterologous promoter.
6. The nucleic acid segment of claim 1, wherein said nucleic acid segment is positioned under the control of a
- 30
- promoter.
5. The nucleic acid segment of claim 1, wherein said nucleic acid segment is positioned under the control of a
- 25
- ID NO:1.
4. The nucleic acid segment of claim 3, wherein said nucleic acid segment has the nucleic acid sequence of SEQ ID NO:1.
- 20
- temperatures of at least 50°C to 70°C.
- ID NO:1 under high conditions of 0.02M-0.15M NaCl at
- SEQ ID NO:1 or a nucleic acid segment hybridizing to SEQ
- consisting essentially of the nucleic acid sequence of
- 15
- nucleic acid segment comprises a nucleic acid sequence
3. The nucleic acid segment of claim 2, wherein said
- 10
- sequence of SEQ ID NO:2.
- wherein said nucleic acid sequence encodes the amino acid
2. The isolated nucleic acid segment of claim 1,
- 5
- An isolated nucleic acid segment comprising a nucleic acid sequence encoding a linalool synthase protein or polypeptide.
1. An isolated nucleic acid segment comprising a

# CLAIMS:

- 91 -

7. The nucleic acid segment of claim 1 further defined as a recombinant vector.

8. The nucleic acid segment of claim 7, wherein said vector is a recombinant expression vector capable of expressing a linalool synthase protein or polypeptide on introduction into a host cell.

9. A plant transformed with the recombinant expression vector of claim 8.

10. The nucleic acid segment of claim 7, wherein said vector comprises a nucleic acid sequence in accordance with SEQ ID NO:1.

11. The nucleic acid segment of claim 7, wherein the vector comprises the pBLUESCRIPT or pBIN19 nucleic acid sequence.

12. A recombinant host cell comprising a nucleic acid segment in accordance with claim 1.

13. The recombinant host cell of claim 12, wherein the host cell is a prokaryotic cell.

14. The recombinant host cell of claim 12, wherein the host cell is a eukaryotic cell.

35

21. A nucleic acid segment which comprises a sequence of at least 15 contiguous nucleotides which corresponds to at least a 15 nucleotide contiguous sequence of SEQ ID NO:1 or its complement.

20. The nucleic acid segment of claim 19 wherein said segment comprises a nucleic acid sequence consisting essentially of the complement of SEQ ID NO:1.

19. A nucleic acid segment hybridizable to the nucleic acid segment of claim 3 under stringent conditions.

18. The recombinant host cell of claim 16, wherein the recombinant expression vector comprises a nucleic acid sequence in accordance with the nucleic acid sequence set forth in SEQ ID NO:1.

17. The recombinant host cell of claim 16, wherein the recombinant vector is a recombinant expression vector and the host cell expresses a thinalool synthase polypeptide.

16. The recombinant host cell of claim 12, wherein the nucleic acid segment is positioned in a recombinant vector.

15. The recombinant host cell of claim 14, wherein the host cell is in a plant.

- 93 -

- 35
- complement.
- at least 500 contiguous nucleotides of SEQ ID NO:1 or its  
contiguous nucleotides which corresponds to a sequence of  
defined as comprising a sequence of at least 500  
26. The nucleic acid segment of claim 25, further
- 30
- complement.
- at least 200 contiguous nucleotides of SEQ ID NO:1 or its  
contiguous nucleotides which corresponds to a sequence of  
defined as comprising a sequence of at least 200  
25. The nucleic acid segment of claim 24, further
- 25
- complement.
- at least 100 contiguous nucleotides of SEQ ID NO:1 or its  
contiguous nucleotides which corresponds to a sequence of  
defined as comprising a sequence of at least 100  
24. The nucleic acid segment of claim 23, further
- 15
- complement.
- at least 50 contiguous nucleotides of SEQ ID NO:1 or its  
contiguous nucleotides which corresponds to a sequence of  
defined as comprising a sequence of at least 50  
23. The nucleic acid segment of claim 22, further
- 10
- complement.
- at least 30 contiguous nucleotides of SEQ ID NO:1 or its  
contiguous nucleotides which corresponds to a sequence of  
defined as comprising a sequence of at least 30  
22. The nucleic acid segment of claim 21, further
- 5



31. The nucleic acid segment of claim 30, further defined as comprising a sequence of at least 2,681 contiguous nucleotides which corresponds to the 2,681 nucleotide sequence of SEQ ID NO:1 or its complement.
30. The nucleic acid segment of claim 29, further defined as comprising a sequence of at least 2,610 contiguous nucleotides which corresponds to a sequence of at least 2,610 contiguous nucleotides of SEQ ID NO:1 or its complement.
29. The nucleic acid segment of claim 28, further defined as comprising a sequence of at least 2,583 contiguous nucleotides which corresponds to a sequence of at least 2,583 contiguous nucleotides of SEQ ID NO:1 or its complement.
28. The nucleic acid segment of claim 27, further defined as comprising a sequence of at least 2,000 contiguous nucleotides which corresponds to a sequence of at least 2,000 contiguous nucleotides of SEQ ID NO:1 or its complement.
27. The nucleic acid segment of claim 26, further defined as comprising a sequence of at least 1,000 contiguous nucleotides which corresponds to a sequence of at least 1,000 contiguous nucleotides of SEQ ID NO:1 or its complement.

35. A method of using a nucleic acid segment encoding a  
linalool synthase protein or polypeptide, comprising the  
steps of:
32. The nucleic acid segment of claim 21, further  
defined as comprising a nucleic acid fragment of up to  
5,000 basepairs in length.
33. The nucleic acid segment of claim 32, further  
defined as comprising a nucleic acid fragment of up to  
3,000 basepairs in length.
34. The nucleic acid segment of claim 21, further  
defined as a DNA segment.
35. A method of using a nucleic acid segment encoding a  
linalool synthase protein or polypeptide, comprising the  
steps of:
- preparing a recombinant vector in which said nucleic  
acid segment is positioned under the control of  
a promoter;
- introducing said recombinant vector into a host  
cell; and
- culturing said host cell under conditions effective  
to allow expression of the encoded linalool  
synthase protein or polypeptide.
36. The method of claim 35, further comprising the step  
of collecting said expressed linalool synthase protein or  
polypeptide.

37. A method of enhancing the scent production of a plant, comprising the steps of:

5 obtaining a recombinant vector capable of expressing the nucleic acid segment of claim 1 on introduction into a plant cell; transforming said plant with said vector; and

10 growing said plant under conditions appropriate for expression of said nucleic acid segment.

15 38. The method of claim 37, wherein said nucleic acid segment is under the control of a tissue specific promoter/enhancer.

20 39. The method of claim 38, wherein said promoter/enhancer is specific for floral tissue.

25 40. The method of claim 38, wherein said plant is a petunia plant.

41. A method of enhancing the flavor of a plant, comprising the steps of:

30 obtaining a recombinant vector capable of expressing the nucleic acid segment of claim 1 on introduction into a plant cell; transforming said plant with said vector; and

35

growing said plant under conditions appropriate for  
expression of said nucleic acid segment.

5 42. The method of claim 41, wherein said nucleic acid  
segment is under the control of a tissue specific  
promoter/enhancer.

10 43. The method of claim 42, wherein said  
promoter/enhancer is specific for fruit tissue.

15 44. The method of claim 43, wherein said plant is a  
tomato plant.

20 45. A purified linanol synthase polypeptide having a  
molecular weight of from about 68 to 79 kDa and a  
specific activity of at least about 20 pkat/mg.

25 46. The polypeptide of claim 45, wherein said  
polypeptide has a specific activity of at least 44.1  
pkat/mg.

30 47. The polypeptide of claim 46, wherein said  
polypeptide has a specific activity of at least 395  
pkat/mg.

35 48. A linanol synthase polypeptide composition obtained  
by separating proteins from a flower or a flower part of  
a *Clarkia breweri* plant and collecting those proteins  
with linanol synthase activity.

49. The linalool synthase polypeptide composition of claim 48, wherein said proteins are separated by the steps of:

5

separating said proteins by ion exchange chromatography and collecting the fractions with linalool synthase activity;

separating said proteins by hydroxyapatite column chromatography and collecting fractions with linalool synthase activity; and

10

separating said proteins by Mono-Q column chromatography and collecting the fractions with linalool synthase activity to obtain said polypeptide composition.

15

50. The polypeptide of claim 48, further defined as consisting essentially of the amino acid sequence of SEQ ID NO:2.

20

51. A recombinant polypeptide comprising as a part of its amino acid sequence, a sequence according to the amino acid sequence set forth as SEQ ID NO:2.

25

52. The polypeptide of claim 51 wherein the polypeptide has the amino acid sequence of SEQ ID NO:2.

30

53. An antibody immunoreactive with the polypeptide of claim 45 or claim 51.

35

54. The antibody of claim 53 wherein said antibody is a monoclonal antibody.

- 100 -

FIG. 1




FIG. 2





FIG. 3  
2/3








FIG. 4  
3/3





WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/52, 15/82, 1/21, A01H 5/00, C07K 16/40		A3	(43) International Publication Date: 1 May 1997 (01.05.97)
(54) Title: USE OF LINALOL SYNTHASE IN GENETIC ENGINEERING OF SCENT PRODUCTION			
(57) Abstract: A purified S-linalool synthase polypeptide from <i>Clarkia breweri</i> is disclosed as is the recombinant polypeptide and nucleic acid sequences encoding the polypeptide. Also disclosed are antibodies immunoreactive with the purified peptide and with recombinant versions of the polypeptide. Methods of using the nucleic acid sequences, as well as methods of enhancing the smell and the flavor of plants expressing the nucleic acid sequences are also disclosed.			
(21) International Application Number: PCT/US96/16482	(22) International Filing Date: 15 October 1996 (15.10.96)	(30) Priority Data: 60/005,146 12 October 1995 (12.10.95)	US
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Wolverine Tower, Room 2071, 3003 South State Street, Ann Arbor, MI 48109-1280 (US).			
(72) Inventor: PICHERSKY, Eran; 325 Burlington Woods Drive, No. 180, Ann Arbor, MI 48104 (US).			
(74) Agent: HIGHLANDER, Steven, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).			
(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
Published Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (88) Date of publication of the international search report: 25 September 1997 (25.09.97)			

(54) Title: USE OF LINALOL SYNTHASE IN GENETIC ENGINEERING OF SCENT PRODUCTION

(57) Abstract:  
A purified S-linalool synthase polypeptide from *Clarkia breweri* is disclosed as is the recombinant polypeptide and nucleic acid sequences encoding the polypeptide. Also disclosed are antibodies immunoreactive with the purified peptide and with recombinant versions of the polypeptide. Methods of using the nucleic acid sequences, as well as methods of enhancing the smell and the flavor of plants expressing the nucleic acid sequences are also disclosed.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

FOR THE PURPOSES OF INFORMATION ONLY

AM	Armenia	GB	United Kingdom	MTW	Malawi
AT	Austria	GR	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NB	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo			SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Cote d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TC	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

# INTERNATIONAL SEARCH REPORT

Inventor Application No  
PCT/US 96/16482

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/52 C12N15/82 C12N1/21 A01H5/00 C07K16/40

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N A01H C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

X	THE PLANT CELL, vol. 7, no. 7, July 1995, pages 1015-1026, XP002036386 MCGARVEY, D.J., ET AL.: "Terpenoid metabolism"	1-3,5-9, 12, 14-17, 19,37-54
Y	see page 1022, left-hand column, last paragraph - right-hand column, last see page 1023, left-hand column, last paragraph - right-hand column	13,35,36
Y	WO 95 11913 A (UNIV WASHINGTON) 4 May 1995 see the whole document	13,35,36 1-12, 14-34, 37-54
A	---	
Y	---	
	---	
	---	

<input checked="" type="checkbox"/>	Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/>	Patent family members are listed in annex.
-------------------------------------	--	-------------------------------------	--

## \* Special categories of cited documents:

- A\* document defining the general state of the art which is not considered to be of particular relevance
- E\* earlier document but published on or after the international filing date
- L\* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- O\* document referring to an oral disclosure, use, exhibition or other means
- P\* document published prior to the international filing date but later than the priority date of the claimed invention
- T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other documents, such combination being obvious to a person skilled in the art.
- Z\* document member of the same patent family

Date of the actual completion of the international search	30 July 1997
Date of mailing of the international search report	0 8.08.97

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentman 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Maddox, A
--	---------------------------------

# INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 96/16482

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TRENDS IN BIOTECHNOLOGY, vol. 13, no. 9, September 1995, pages 350-355, XP002024912 MOL J N M ET AL: "FLORICULTURE: GENETIC ENGINEERING OF COMMERCIAL TRAITS" see page 354, left-hand column, last paragraph - right-hand column, paragraph 1</p> <p>--- CHEMICAL ABSTRACTS, vol. 122, no. 15, 10 April 1995 Columbus, Ohio, US: abstract no. 181648, PICHERSKY, ERAN ET AL: "Purification and characterization of S-linalool synthase, an enzyme involved in the production of floral scent in Clarkia breweri" XP002036391 see abstract &amp; ARCH. BIOCHEM. BIOPHYS. (1995), 316(2), 803-7 CODEN: ABBI44; ISSN: 0003-9861, PLANT CELL 8 (7), 1996, 1137-1148. , July 1996, XP002036387 DUDAREVA N ET AL: "Evolution of floral scent in Clarkia: Novel patterns of S-linalool synthase gene expression in the C. breweri flower." see the whole document</p> <p>--- PLANT PHYSIOLOGY (ROCKVILLE) 106 (4). 1994, 1533-1540. , XP002036388 PICHERSKY E ET AL: "Floral Scent Production in Clarkia (Onagraceae): I. Localization and Developmental Modulation of Monoterpene Emission and Linalool Synthase Activity." see the whole document</p> <p>--- THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 31, 1993, pages 23016-23024, XP002036389 COLBY, S.M., ET AL: "4S-limonene synthase from the oil glands of spearmint (Mentha spicata)" see the whole document</p> <p>--- -/--</p>	<p>1-3,5-9, 12, 14-17, 19, 37-40, 45-54</p> <p>1-3, 45-54</p> <p>1-4,12, 13,16, 19,45-54</p> <p>1-54</p> <p>13,35,36</p>

# INTERNATIONAL SEARCH REPORT

Inventor: AI Application No  
PCT/US 96/16482

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 118, no. 23, 7 June 1993 Columbus, Ohio, US; abstract no. 230249, SPENCER, ANDREW ET AL: "In vitro biosynthesis of monoterpenes by Agrobacterium transformed shoot cultures of two Mentha species" XP002036392 see abstract & PHYTOCHEMISTRY (1993), 32(4), 911-19 CODEN: PYTCAS;ISSN: 0031-9422, --- BIOTECHNOLOGY, vol. 12, no. 1, January 1994, page 64 XP002036390 PELLEGRINESCHI, A., ET AL.: "Improvement of ornamental characters and fragrance production in lemon-scented geranium through genetic transformation by Agrobacterium rhizogenes" see the whole document WO 92 16611 A (PERNOD RICARD: KARST FRANCIS (FR): JAVELOT CATHERINE JEANNIE ELIA) 1 October 1992 see the whole document WO 92 06206 A (ICI PLC) 16 April 1992 see page 3, line 33 - line 35 --- WO 93 07257 A (SMART PLANTS INTERNATIONAL INC) 15 April 1993 see page 2, line 11 - line 23 -----	37
A	37	37
A	41	41
A	41	41
A	41	41

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No  
PCT/US 96/16482

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
---	---------------------	----------------------------	---------------------

WO 9511913 A	04-05-95	AU 8127994 A CA 2118071 A EP 0730603 A	22-05-95 29-04-95 11-09-96
--------------	----------	--	----------------------------------

WO 9216611 A 01-10-92 NONE

WO 9206206 A	16-04-92	AU 8641391 A EP 0552207 A	28-04-92 28-07-93
--------------	----------	------------------------------	----------------------

WO 9307257 A	15-04-93	AU 2807592 A EP 0638120 A	03-05-93 15-02-95
--------------	----------	------------------------------	----------------------





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/52, 15/82, 1/21, A01H 5/00, C07K 16/40	A3	(43) International Publication Date: 1 May 1997 (01.05.97)
(11) International Publication Number: WO 97/15584		

(21) International Application Number: PCT/US96/16482	(22) International Filing Date: 15 October 1996 (15.10.96)	(30) Priority Data: 60/005,146 12 October 1995 (12.10.95) US	(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]: Wolverine Tower, Room 2071, 3003 South State Street, Ann Arbor, MI 48109-1280 (US).	(72) Inventors; and (75) Inventor/Applicants (for US only): PICHERSKY, Eran; 325 Burlington Woods Drive, No. 180, Ann Arbor, MI 48104 (US).	(74) Agent: HIGHLANDER, Steven, L.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).
(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).					
Published Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.					
(88) Date of publication of the international search report: 25 September 1997 (25.09.97)					

(54) Title: USE OF LINALOOL SYNTHASE IN GENETIC ENGINEERING OF SCENT PRODUCTION

(57) Abstract

A purified S-linalool synthase polypeptide from *Clarkia breweri* is disclosed as is the recombinant polypeptide and nucleic acid sequences encoding the polypeptide. Also disclosed are antibodies immunoreactive with the purified peptide and with recombinant versions of the polypeptide. Methods of using the nucleic acid sequences, as well as methods of enhancing the smell and the flavor of plants expressing the nucleic acid sequences are also disclosed.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KR	Korea	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LT	Lithuania	SG	Singapore
CH	Switzerland	LK	Sri Lanka	SI	Slovenia
CI	Cote d'Ivoire	LV	Latvia	SK	Slovakia
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Monrovia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam